The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission. by Santos da Silva, Eveline(*) et al.
RESEARCH ARTICLE
The Envelope Cytoplasmic Tail of HIV-1
Subtype C Contributes to Poor Replication
Capacity through Low Viral Infectivity and
Cell-to-Cell Transmission
Eveline Santos da Silva1☯, Martin Mulinge1☯, Morgane Lemaire1, Cécile Masquelier1,
Cyprien Beraud1, Arkadiusz Rybicki1, Jean-Yves Servais1, Gilles Iserentant1, Jean-
Claude Schmit1,2, Carole Seguin-Devaux1, Danielle Perez Bercoff1*
1 Department of Infection and Immunity, Luxembourg Institute of Health, 29 rue Henri Koch, L-4354 Esch-
sur-Alzette, Luxembourg, 2 Centre Hospitalier de Luxembourg, Service National des Maladies Infectieuses,
4 Rue Ernest Barblé L-1210 Luxembourg, Luxembourg
☯ These authors contributed equally to this work.
* danielle.perezbercoff@lih.lu
Abstract
The cytoplasmic tail (gp41CT) of the HIV-1 envelope (Env) mediates Env incorporation into
virions and regulates Env intracellular trafficking. Little is known about the functional impact
of variability in this domain. To address this issue, we compared the replication of recombi-
nant virus pairs carrying the full Env (Env viruses) or the Env ectodomain fused to the
gp41CT of NL4.3 (EnvEC viruses) (12 subtype C and 10 subtype B pairs) in primary CD4+
T-cells and monocyte-derived-macrophages (MDMs). In CD4+ T-cells, replication was as
follows: B-EnvEC = B-Env>C-EnvEC>C-Env, indicating that the gp41CT of subtype C con-
tributes to the low replicative capacity of this subtype. In MDMs, in contrast, replication
capacity was comparable for all viruses regardless of subtype and of gp41CT. In CD4+ T-
cells, viral entry, viral release and viral gene expression were similar. However, infectivity of
free virions and cell-to-cell transmission of C-Env viruses released by CD4+ T-cells was
lower, suggestive of lower Env incorporation into virions. Subtype C matrix only minimally
rescued viral replication and failed to restore infectivity of free viruses and cell-to-cell trans-
mission. Taken together, these results show that polymorphisms in the gp41CT contribute
to viral replication capacity and suggest that the number of Env spikes per virion may vary
across subtypes. These findings should be taken into consideration in the design of
vaccines.
Introduction
Spread of Human Immunodeficiency Virus (HIV-1) to new target cells in vitro and in vivo
occurs via infection with free virions or by direct transmission of newly synthesized virions
budding from an infected “donor” cell to a nearby target cell [1–8] reviewed in [9, 10]. Both
modes of infection are mediated by the viral envelope (Env). Env is a highly glycosylated
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trimeric complex composed of a surface subunit (gp120) and a transmembrane anchoring sub-
unit (gp41) which are non-covalently linked [11]. The 2 Env subunits result from the proteo-
lytic cleavage of the trimeric gp160 precursor protein by the cellular protease Furin in the Golgi
apparatus [12, 13]. The surface subunit gp120 ensures viral adsorption and binding to the CD4
receptor [14–16] and the coreceptor (CCR5 or CXCR4) [17–20]. These interactions induce a
series of conformational changes in Env and lead to the insertion of the fusion peptide located
at the N-terminus of the transmembrane subunit gp41 into the target cell membrane and to
fusion of the viral and cellular membranes [21–27]. The Env surface subunit gp120 and the
extracellular portion of gp41 have been extensively studied, but the cytoplasmic domain of Env
(gp41CT) has been granted far less attention and many of its functions remain poorly under-
stood or speculative.
The gp41CT of lentiviruses, including HIV-1, is unusually long (~150 amino acids (AA)) in
comparison to other retroviruses (< 50 AA) [28]. Immediately downstream of the membrane-
spanning domain (MSD) lies the immunodominant Kennedy polypeptide sequence followed
by three highly conserved α-helix domains referred to as the lentivirus lytic peptides (LLP):
LLP-2 (AA 773–793) which overlaps the LLP-3 leucine zipper domain (AA 785–807), and
LLP-1 (AA 833–856) [29]. Despite considerable sequence variation, the physicochemical and
structural properties of peptides spanning the LLP regions are believed to be conserved across
HIV types and HIV-1 subtypes [30].
The gp41CT of lentiviruses ensures several functions (recently reviewed in [31–35]). The
main function of the gp41CT is to ensure Env packaging into nascent virions, by interacting
with the matrix protein (MA) at the N-terminus of the p55Gag precursor [36–48]. The MA/
gp41CT interaction maps to charged AA within LLP-2 and to the PT/RRIR domain of LLP-1
[38–44], but whether it is direct or indirect remains a matter of debate [31, 49–56]. The
gp41CT also regulates Env trafficking to and from the plasma membrane (PM) through the
Trans Golgi Network (TGN). As soon as it reaches the membrane, Env is internalized [57–59],
following its interaction with the AP-2 μ (medium) chains via the highly conserved Y712SPL
[60–62] and the C-terminal LL856 [63, 64] Golgi retrieval signals. Endocytosed Env can either
proceed to be degraded by lysosomes or be sorted back to the Golgi by interacting with retro-
mer components Vps26 and Vps35 via is1 and is2 [65] or with a number of other proteins
which regulate its traffic through the TGN and back to the PM. These include TIP47 through
the Y802W803 diaromatic motif [50–54], AP-1 and AP-3 through the Y712SPL and the C-termi-
nal dileucine LL856 motifs [61, 63, 64] and Rab11a/FIP1C and Rab14 through the YW795 diaro-
matic motif [55, 66]. AP-2-mediated internalization of Env is reversed by the p55Gag
polyprotein precursor, and it was proposed that Env internalization is a means to evade
immune recognition and proceeds until sufficient Gag has assembled at the PM to trap Env
into the budding virion [67, 68]. The gp41CT also contributes to viral infectivity of Env and to
cell-to-cell transmission by maintaining the structure of Env [69–73]. The gp41CT Y712SPL
motif induces polarization of p55Gag at the basolateral membrane in polarized non-human
cell lines [74–76] and in T-cells [73, 77]. In the mature virion, it enables Env clustering, a pre-
requisite of efficient infectivity [78–82]. Last but not least, the gp41CT was reported to favor
viral transcription through direct and indirect mechanism. Recently, the gp41CT of HIV and
of SIV have been shown to contribute to cell activation by inducing the canonical NF-κB path-
way through Y768 within the YHRL motif of LLP-2 [83]. Indirect mechanisms involve the relief
of the RhoA-mediated transcriptional inhibition by interacting with p155-RhoGEF [84, 85]
and induction of LTR-driven transcription by targeting the precursor of luman, a repressor of
Tat-mediated HIV transcription, for proteasomal degradation [86].
gp41CT-truncated viruses display a cell-type dependent phenotype and are unable to repli-
cate in a number of T cell lines (H9, MT-2, Jurkat and CEMx174) and in primary target cells
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(primary CD4+ T-cells and macrophages), referred to as “non-permissive cells”. In other cell
lines (MT-4 and M8166, HEK, HeLa, and COS), in contrast, the impact of such truncations is
limited (“permissive cells”) [38, 39, 42, 44, 73, 87–89]. The non-permissive phenotype has been
associated with decreased Env incorporation into virions [42–44, 70, 90, 91], irrespective of the
levels of Env at the cellular PM [41, 42, 87, 88].
Env variability and subtype-related specificities have long been acknowledged in studies
investigating the Env ectodomain and in vaccine design. Yet most mutational or biochemical
studies addressing the role of the gp41CT have been performed using the laboratory-adapted
strain NL4.3 with mutations in charged residues or disrupted dileucine motifs. Few studies
have addressed the role of polymorphisms in the gp41CT. One biochemical study suggests its
biophysical properties are likely conserved despite type and subtype specific polymorphisms
[30] and two studies have investigated the impact of specific mutations in the Y712SPL and
Y802W803 trafficking motifs [53] or of LLP-1 truncations occurring in patient samples on viral
replication and Env intracellular distribution, as well as the role of MA in rescuing such defects
[91]. Studies examining the functional impact of non-subtype B polymorphisms on viral repli-
cation and virion infectivity are missing. Here we compared the infectivity of viruses with sub-
type C Envs to viruses with the extensively studied subtype B envs in primary CD4+ T-cells
and monocyte-derived-macrophages (MDMs) in vitro. Subtype C is the most widely spread
subtype, accounting for> 52% of infections worldwide [92]. In vitro, subtype C viruses have
lower replication capacity than subtype B or D viruses, owing to Env [93–97]. We therefore
enquired whether the gp41CT also contributed to the lower replication capacity of subtype C
viruses in vitro. Using recombinant virus pairs differing only by their gp41CT in an otherwise
constant viral backbone, we found that CD4+ T-cells but not MDMs infected with viruses har-
boring subtype C Envs produced less virions than viruses with subtype B Envs. The gp41CT
substantially accounted for this defect in propagative infection as it enabled less Env incorpo-
ration into virions and poor cell-to-cell transmission. Subtype C MA only minimally restored




HEK 293T and TZM-bl cells (ATCC through the NIH AIDS Research and Reference Reagent
Program) were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% Fetal Calf Serum (FCS), 2 mM L-Glutamine, 50 μg/mL Penicillin and 50 μg/mL
Streptomycin (all from Invitrogen, Merelbeke, Belgium).
Isolation and culture of primary cells
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained
from healthy volunteer HIV-1 seronegative donors (Red Cross Luxembourg) by Lymphoprep
density gradient centrifugation (Axis-Shield, Oslo, Norway). CD4+ T-cells were isolated from
PBMCs by negative selection using antibody coated-beads (Miltenyi Biotec, Leiden, Nether-
lands) and cultured in RPMI 1640 medium supplemented with 10% FCS, 2mM L-Glutamine,
50 μg/mL Penicillin and 50 μg/mL Streptomycin (all from Invitrogen, Merelbeke, Belgium)
(CD4 medium). PBMCs were stimulated with 5 μg/ml PHA-P (Sigma, Borneim, Belgium) for
48 hours, then with 10 U/ml interleukin 2 (IL-2, Roche, Mannheim, Germany) for 24 hours
before infection.
Monocytes were isolated from fresh PBMCs by adherence to plastic for 1 hour at 37°C in
MDMmedium (RPMI 1640, 2mM L-Glutamine, 50 μg/mL Penicillin and 50 μg/mL
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Streptomycin, 10 mMHEPES, 1% MEM vitamins, non-essential amino acids, 50 μM β-mer-
captoethanol, 1 mM sodium pyruvate) (all from Invitrogen, Merelbeke, Belgium) supple-
mented with 2% human AB serum (Sigma, Bornem, Belgium) as described in [98]. Adherent
monocytes were seeded in 96-well plates (3x105 cells/well) and allowed to differentiate into
macrophages for 7 days in MDMmedium supplemented with 15% human AB serum.
Viral Samples
Plasma samples from 22 treatment-naive patients infected with HIV-1 subtypes B (10 patients)
and subtype C (12 patients) were included in the study. Ethical approval was obtained from the
Comité National d’Ethique pour la Recherche in Luxembourg (approval number: 201105/07).
Patients provided written informed consent. Mean plasma viral load (VL) (Abbott m2000
RealTime HIV-1 assay) and CD4 counts were comparable for patients infected with either sub-
type: mean VL for subtype B was 34181 RNA copies/ml [range: 635–124657] and mean VL for
subtype C was 38223 RNA copies/ml [range: 1759->500000]; mean CD4 count was 386 cell/
mm3 [range: 110–610] for subtype B-infected patients and 368 [range: 100–760] for subtype
C-infected patients. HIV-1 subtype was assigned from HIV-1 PR-RT and Env sequences
(V3-loop and gp41CT) using COMET [99] and the REGA HIV subtyping tool [100]. A phylo-
genetic tree (GTR+G model) with 1000 bootstrap values was inferred for the PR-RT and
Env gp41CT sequences with RAxML version 7.6.0 using reference strain G.BE.96.DRCBL.
AF084936 as the outgroup. Phylogenetic analysis confirmed the samples were unrelated (data
not shown). Coreceptor usage was determined as described in [101]. Subtype B samples included
7 strictly R5, 1 R5/X4 and 2 strictly X4 strains; 8 subtype C strains were strictly R5 and 4 were
R5/X4. Two reference clones with identical gp41CTs, NL4.3 (X4 tropic) [102] and NLAD8 (R5
tropic) [103], were included as controls in all experiments. Of note, NLAD8 contains the ectodo-
main of ADA and the gp41CT from NL4.3, downstream of the BamHI site [103].
Env amplification
One ml of HIV-1 positive plasma was centrifuged at 24 000g for 1 hour at 4°C and viral RNA
was extracted from the pellet using the Qiagen Viral RNA extraction kit (Qiagen, Hilden, Ger-
many). Viral cDNA was synthesized in a one-step RT-PCR reaction using forward primer
KVL008 and reverse primer KVL009 [104] as described in [101]. A nested PCR was performed
from 2 μl of cDNA using forward primer rec.envHXB2_Fp (50-TAGGCATYTCCTATGGCA
GGAA'-3’) and reverse primer rec.HR1-2_RP (5’-CTCTCTCTCCACCTTCTTCTTC-3’) to
amplify the Env ectodomain (EnvEC, gp140) or subtype-dependent reverse primers Rp-full-
Env-B (5’-TCGTCTCATTCTTTCCCTTAC-3’) and Rp-fullEnv-C (5’-TCMTCTYATTCTTT
CYCTTAC-3’) respectively for subtype B and C the full Env sequence (Env, gp160). Nested
PCR reactions were performed using 2.5 U Platinum TaqHigh Fidelity over 35 cycles (95°C
for 30 sec, 48°C for 30 sec and 68°C for 3 min), and a final 10 min extension at 68°C. Amplifica-
tion was verified by agarose gel electrophoresis. To avoid PCR selection, for each sample five
independent amplifications were performed in parallel and pooled. Gp41CT sequences are
available under GenBank accession numbers HG313608-HG313634.
Construction of viral backbones
pNL4.3ΔEnv (Fig 1A) and pNL4.3ΔEnvEC (Fig 1B) were generated by deleting the full env or
the env ectodomain (EnvEC) from pNL4.3 respectively by inverse PCR and replacing it by a
AfeI restriction site for linearization. To construct pNL4.3ΔEnv, the EcoRI-XhoI fragment from
pNL4.3 was subcloned into pBluescript KS+ (Stratagene, Amsterdam, Netherlands), the entire
envelope (gp160) was deleted from pBluescript.Env by inverse PCR using phosphorylated
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primers Rp_del.full.Env: 5'-GCTGTCTTCTGCTCTTTCTATTAG-3' and Fp_del.full.Env: 5'-
GCTATGGGTGGCAAGTGGTC-3' designed to introduce a AfeI restriction site (underlined),
DpnI digested and ligated to create pBluescriptΔEnv.AfeI. The EcoRI–XhoI fragment from
pBluescriptΔEnv.AfeI was transferred back to pNL4.3. To construct pNL4.3ΔEnvEC, the Sal-
I-XhoI fragment from pNL4.3ΔEnv.EC.Luc [105] was cloned into pNL4.3. All constructs were
sequenced.
Fig 1. Generation of recombinant viruses andmolecular constructs pNL4.3ΔEnv and pNL4.3ΔEC. A and B: The molecular constructs were
based on the pNL4.3 infectious clone deleted of the entire Env (gp160, ΔEnv) (A) or of the Env gp120+gp41 ectodomain (gp140, ΔEnvEC) (B) by
inverse PCR. The deleted portion is replaced by the AfeI restriction site for linearization prior to transfection.C: Infectious viral particles expressing
patient-derived Env or EnvEC sequences were generated by co-transfecting HEK 293T cells with the linearized pNL4.3ΔEnv or pNL4.3ΔEC
backbones and a PCR amplicon spanning the target region (gp160 (Env) or gp140 (EnvEC) respectively).
doi:10.1371/journal.pone.0161596.g001
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To introduce subtype CMA into pNL4.3ΔEnv, thematrix sequences of subtype C strains 1671
and 0266 were amplified using forward primer 0266-BssHI-F: 5’-ACTCGGCTTGCTGAAGCGCG
CTCG-3’ containing BssHII (underlined) and reverse primer 0266-SphI-R: 5’-TGCATGCAGGG
CCTRTTGCACC-3’ containing the SphI restriction site (underlined). The BssHII-SphI digested
PCR product was cloned into the BssHII-SphI digested pNL4.3ΔEnv backbone and the constructs
were sequenced after cloning to ensure conformity of the clonedMA to the bulk sequence.
Production of Env and EnvEC Recombinant Viruses
To produce recombinant viral particles, 2.5x106 HEK 293T cells were cotransfected with 8 μg
of AfeI-linearized pNL4.3ΔEnv or pNL4.3ΔEnvEC backbones and patient-derived Env PCR
amplicons (10 μl of EnvEC amplicon and 30 μl full Env amplicon) (Fig 1C) using Lipofecta-
mine 2000 (Invitrogen, Merelbeke, Belgium). Cell-free culture supernatants were collected 48
hours later, clarified by centrifugation and stored at -80°C until use. Viral production was
determined by quantifying p24 capsid protein using a p24 ELISA test (Innogenetics, Belgium).
Amplicons produced from pNL4.3 (X4) and pNLAD8 (R5) plasmids were used as positive con-
trols and viral-like particles lacking an envelope produced by transfecting the linearized back-
bones alone were used to assess background noise.
Infections
Activated CD4+ T-cells (105 cells/well) or MDMs (3x105 cells/well) were infected in 96-well
plates with normalized amounts of Env and EnvEC recombinant virus pairs (1 ng/ml (CD4+ T-
cells) or 3 ng/ml (MDM) equivalent p24) by spinoculation (1200 g for 2 hours at 25°C), followed
by a 1 hour- (for CD4+ T-cells) or 2 hour- (for MDMs) incubation at 37°C and washing. Viral
supernatants were collected every 3–4 days and stored at -80°C until use. All infections were per-
formed in triplicate or quadruplicate wells. Viral replication was assayed by measuring p24 in cul-
ture supernatants by ELISA (Innogenetics, Belgium). Because gp41CT truncations in primary
CD4+ T-cells and in non-permissive T-cells lines can be overridden by high viral gene expression
such as those reached at saturating viral inputs [73], preliminary experiments with 10 ng/ml, 3 ng
and 1 ng/ml were conducted to identify viral inputs that reproducibly infected primary CD4+ T-
cells and MDMs without saturating the system (data not shown). For some control experiments,
10 μMAZT (Sigma, Bornem, Belgium) were added to ensure only de novo viral replication was
measured. In some experiments, polybrene (5 μg/ml) was added at the time of infection.
TZM-bl cells (HeLa-derived cells expressing CD4, CCR5 and LTR-luc) (2x104 cells/well) were
infected with 2 ng/ml equivalent p24 in the same conditions as CD4+ T-cells or MDMs and lucif-
erase was measured in cell lysates 48 hours post-infection using the Promega luminescence kit.
Virus tethered to the PM
To measure virus tethered to the PM, CD4+ T-cells were infected for 5 days as above, washed
once with PBS and incubated for 15 min at 37°C in 100 μl of Tris/HCl (pH 8.0) with 150 mM
CaCl2 with or without 1 mg/ml subtilisin (Sigma). The reaction was stopped with PMSF (5mM
in 0.5 ml FCS-supplemented culture medium) and p24 in each fraction was measured by
ELISA. The amount of virus released after protease treatment was related to total virus, i.e. p24
released in viral supernatants+p24 bound to the PM.
Cell-to-cell transmission
CD4+ T-cells (4x105/well) in sextuplicates were infected with 1 ng/ml recombinant C-Env or
C-EnvEC viruses by spinoculation as described above. After 48 hours, CD4+ T-cells (donor
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cells) were washed extensively and co-cultured with TZM-bl target cells for 48 hours. 1 μM
indinavir (IDV) was added in half the wells to control for infection by free virus. The next
morning, 1 μMAMD3100 and 1μMTAK-779 were added to limit replication to a single cycle.
Transmission to TZM-bl cells was assessed by measuring luciferase after removal of CD4+ T-
cells and washing of target cells. To control for the contribution of free virus, the supernatant
of the co-cultures was collected and used to infect TZM-bl cells.
Western Blot
To monitor Env incorporation into viral particles, supernatants from transfected HEK 293T
cells and from infected CD4+ T-cells were purified on a sucrose cushion composed of a 10%-
60% sucrose cushion using a Beckman Optima MAX Ultracentrifuge at 50 000 rpm for 16
hours at 4°C. The fractions containing purified virions were harvested and concentrated at 25
000 rpm for 16 hours at 4°C. Virus content in CD4+ T-cell supernatants was too low to be
detected by ELISA, WB or silver staining despite repeated attempts. Ultracentrifuged crude
supernatant was therefore used. The samples were lysed at 95°C for 10 min with reducing
Laemmli buffer and resolved on 10% SDS-PAGE gels. For immunoblotting, proteins were
transferred to nitrocellulose membranes and probed overnight at 4°C with goat anti-HIV-1
gp120 (ab53937) and mouse anti-HIV-1 p24 clone 39/6.14 (Abcam, Cambridge UK) antibod-
ies. Secondary antibodies were donkey anti-goat and rabbit anti-mouse IgG conjugated to HRP
(Sigma-Belgium).
For analysis of intracellular viral proteins, triplicate wells of infected CD4+ T-cells were
washed and pooled. 10 μg of protein were mixed with reducing Laemmli buffer and resolved
on 12% SDS-PAGE gels. For immunoblotting, rabbit α-p55Gag+p17+p24 ab63917 (1/1000)
(Abcam), goat anti-HIV-1 gp120 (ab53937) and rabbit anti-β-actin (Cell Signaling #49675)
were used. After washing, membranes were incubated sequentially with donkey anti-goat IgG,
then with goat anti-rabbit IgG, both conjugated to HRP (Sigma-Belgium) and developed using
ECL (Amersham).
Images were acquired with a GE Healthcare ImageQuant LAS 4000 and bands correspond-
ing to viral proteins in each lane were quantified using ImageJ and normalized to β-actin to
estimate their relative amount.
Statistical analyses
Statistical analyses were performed using GraphPad Prism v 5.01, applying a paired t-test for
pairs of EnvEC and Env viruses within a given subtype (i.e C-EnvEC and C-Env viruses or
B-EnvEC and B-Env viruses) and a Kruskal-Wallis test for comparisons between subtypes (e.g.
C-EnvEC and B-EnvEC viruses, C-Env and B-Env viruses, C-EnvEC and B-Env viruses). Sta-
tistical relevance was considered if p< 0.05. The standard deviation between results from inde-
pendent experiments is reported.
Results
The gp41CT contributes to the lower replication of subtype C viruses in
CD4+ T-cells but not in MDMs
To assess whether naturally occurring polymorphisms in the gp41CT impact viral replication,
we used a comparative approach based on NL4.3-derived paired recombinant viruses contain-
ing patient-derived sequences spanning the full env (gp160 –Env viruses) or the env ectodo-
main and transmembrane domain (gp140 –EnvEC viruses) (Fig 1). With this approach,
replicating viral particles differing only by the gp41CT (patient-derived vs NL4.3-derived) and
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reflecting the heterogeneity of quasispecies are obtained. Twelve subtype C and 10 subtype B
patient-derived strains were included. To validate the system, we verified that Env and EnvEC
virus pairs carrying the Env or EnvEC of the controls NL4.3 and NLAD8 had similar replica-
tion in CD4+ T-cells (Fig 2A–2D) and in MDMs (Fig 2E–2G), given that both carry the
gp41CT from NL4.3.
Viral replication was followed over 10 days. As can be seen from Fig 2A and 2B, infection of
CD4+ T-cells with subtype B viruses did not show great variability within pairs, regardless of
the gp41CT, while for viruses with subtype C Envs, C-Env virus released in supernatants
remained lower than the corresponding C-EnvEC virus. Replication of viruses with subtype C
gp41CT plateaued after day 5 and the difference in viral replication was amplified over time,
suggestive of hindered propagative infection. To ease comparison and to include infection
experiments with sufficient different donors, viral production in CD4+ T-cell culture superna-
tants was compared 5 days post-infection. Production of viruses with subtype B Env or EnvEC
at day 5 post-infection was comparable and was significantly higher than replication of C Env
and C-EnvEC viruses in the following order B-Env = B-EnvEC> C-EnvEC> C-Env viruses at
all time points (Fig 2C and 2D). For subtype C Env pairs, at this time-point viral production of
C-Env viruses was 5-10-fold lower than their chimeric C-EnvEC counterpart in 6/12 cases
(“intermediate” replication capacity), and in 5/12 cases it was over 10-fold lower (“low” replica-
tion capacity) (Fig 2D). In one case (strain 0978), replication was similar for both or higher for
C-Env viruses, depending on donor cells (Fig 2D).
In MDMs, in contrast, no difference between subtypes (p>0.05, unpaired t-test) nor
between paired recombinants was recorded (Fig 2E) over 14 days of culture (p>0.05, paired t-
test) (Fig 2F and 2G), indicating that the subtype of the gp41CT did not modify replication lev-
els in this cell type. AZT fully abrogated viral replication in MDMs (not shown), confirming
that p24 detected in MDMs corresponded to de novo viral production and not to virus inocu-
lum bound to cells.
These results confirm that the viral Env is an essential driver of viral replication [94, 95, 97,
106] and show that not only the Env ectodomain, but also the gp41CT contributes to viral rep-
lication capacity in CD4+ T cells in vitro. These results also show that in macrophages, replica-
tion is comparable regardless of Env and of the gp41CT. Sequence analysis (S1 Fig) showed
conservation of subtype B gp41CT and highlighted subtype C-specific polymorphisms. Yet no
obvious link between polymorphisms and replication levels could be identified.
Lower viral replication of C-Env viruses is not due to lower viral gene
expression
To gain some insight into the lower viral replication of C-Env viruses in CD4+ T-cell cultures,
viral protein levels and profiles were examined at day 5 post-infection. As can be seen from Fig
3A, cells infected with B-EnvEC and B-Env viruses displayed comparable viral protein levels
and profiles, while cells infected with C-Env and C-EnvEC viruses showed lower viral protein
levels. More specifically, whereas different Gag forms (p55Gag, p41Gag, p24 and p17) and Env
(gp160 and gp120) were readily detected in CD4+ T-cells infected with subtype B viruses and
C-EnvEC viruses, only p55Gag and p41Gag were detected in CD4+ T-cells infected with
C-Env viruses, while mature forms of Gag (p24 and p17) and Env (gp160 and gp120) remained
consistently lower or undetectable (Fig 3B). β-actin levels did not fluctuate with mature forms
of Gag or with Env levels, arguing against higher cell death. Furthermore, cell death, as mea-
sured with an MTT assay, correlated with p24 measured in culture supernatants (not shown).
Therefore, the lower viral protein levels recorded in day-5 cell lysates likely reflect lower or
slower viral and are in line with the lower viral production recorded at this time point (Fig 2A–
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Fig 2. Viruses with subtype C gp41CT have lower replication than viruses with subtype B gp41CT in
CD4+ T-cells but not in MDMs. A and B. Replication of subtype B and subtype C recombinants in CD4
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 9 / 29
2D). Accordingly, p24 released in the supernatant paralleled intracellular mature forms of Gag
(p24+p17) for all recombinant viruses at day 5 (Spearman r = 0.5683, p<0.0001) (Fig 3A).
It has been suggested that low intracellular mature forms of Gag reflect low gene expression
from the LTR [73]. Moreover, the gp41CT was reported to de-repress viral transcription from
the LTR [84–86] and to induce nuclear translocation of NF-κB p65/RelA [83]. To assess
whether low viral protein expression underlies the lower viral production recorded in CD4+ T-
cell cultures infected with C-Env viruses or whether lower viral protein expression merely
reflect lower or slower viral replication, proteins in CD4+T-cell lysates were quantified 40
hours post infection. Polybrene had to be added to CD4+ T-cells exposed to C-EnvEC and
C-Env viruses because in its absence, no p55Gag could be detected for these viruses at this
early time point. As shown in Fig 3B, the expression of the viral gene product p55Gag was com-
parable between C-EnvEC and C-Env viruses.
In MDM lysates, viral replication levels were too low to be detected by WB (not shown).
Taken together, these observations argue against the possibility that differences in viral protein
expression account for the differences in viral production we recorded and suggest that lower viral
protein expression rather reflects a delay of a defect in later steps of the viral replication cycle.
Viral release is not impaired
We next considered the possibility that viruses might remain tethered at the PM, consequent to
intrinsic properties of virions with subtype C gp41CT or to recombinant B-C Vpu. To investigate
this hypothesis, virus tethered to the PM of CD4+ T-cells was released by subtilisin digestion. Fig 4
illustrates that there was no difference in the amount of virus which remained attached to CD4+ T-
cells infected with EnvEC or with the corresponding Env recombinant for subtype B or for subtype
C Envs, arguing against the possibility that the observed phenotype is a Vpu-related bias or
involves a tetherin-like activity of subtype C gp41CT interfering with viral release.
C-Env virions produced by CD4+ T-cells, but not by HEK293T cells, are
less infectious
We then inquired whether the gp41CT affected the infectivity of C-Env virions compared to
their C-EnvEC counterpart. We therefore measured the infectivity of Env and EnvEC
+ T-cells from two different donors. 105 CD4+ T-cells were infected with equivalent amounts (1 ng/ml) of
Env or EnvEC recombinant viruses. Infection was monitored by measuring p24 in culture supernatants at
days 2 or 3, 4 or 5, 7 and 9 or 10. Examples of replication in CD4+ T cells of two different donors are shown
after infection with subtype B (left panels) and subtype C (right panels) Env and EnvEC recombinant viruses.
All infections were performed in triplicate wells. (C and D) P24 in supernatants of 105 CD4+ T-cells 5 days
post-infection. The same results at day 5 post-infection are presented and statistically significant means
(paired t-test for viral pairs, unpaired t-test for inter-subtype comparisons) are indicated (C). In panel (D), the
results are shown per pair. The ratio of p24 released in supernatants of cells exposed to Env recombinant
viruses divided by p24 in the supernatants of cells exposed to the corresponding EnvEC recombinant virus is
reported. A positive ratio indicates that the full Env recombinant replicates better than its EnvEC counterpart
containing the gp41CT of NL4.3. A negative ratio implies the EnvEC recombinant virus replicates better than
the Env recombinant. Because of inter-donor variability, results are presented as individual experiments
performed with CD4+ T-cells from independent donors. E. Replication of subtype B and subtype C
recombinants in MDMs. 105 MDMs were infected with equivalent amounts (3 ng/ml) of subtype B (left panel)
and subtype C (right panel) Env and EnvEC recombinant viruses. Infection was monitored by measuring p24
in culture supernatants at days 3, 7, 10 and 14. All infections were performed in triplicate or quadruplicate
wells. (F and G) p24 in supernatants of 3x105 MDMs 7 days post-infection. All infections were performed
in triplicate or quadruplicate wells. Standard deviation is indicated. In panel (G), the same results as in panel
(F) are represented for each individual strain. The ratio of p24 released in supernatants of cells exposed to
Env recombinant viruses divided by p24 in the supernatants of cells exposed to the corresponding EnvEC
recombinant virus is reported. Tropism is indicated as follows: R5: blue circle; X4: red circle; R5X4: purple
circle.
doi:10.1371/journal.pone.0161596.g002
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Fig 3. Lower replication of C-Env recombinants in CD4+ T-cells is not associated with lower viral gene
expression. A and B. Western Blot analyses of intracellular Env and Gag in CD4+ T-cells exposed to
subtype B and subtype C recombinant virus pairs at day 5 post infection (A) and 40 hours post infection
(B). CD4+ T-cells (105 cells/well) infected in triplicate wells for 5 days (A) or for 40 hours (B) were washed,
pooled and lysed in 75μl of reducing Lämmli buffer. Polybrene was added at the time of infection of C-EnvEC
and C-Env virions for WB detection in 40-hour lysates. Proteins were resolved by SDS-PAGE and
immunoblotted with a rabbit polyclonal antibody recognizing the immature p55Gag immature precursor and the
mature p17 and p24 proteins, and a goat polyclonal antibody against gp120. β-actin was immunoblotted to
control for loading. The corresponding supernatant (30 μl) were immunoblotted using a mouse monoclonal
antibody against p24. One representative experiment of three is shown. Samples are arranged by subtype to
ease visual comparison. C and B Env samples were also run on the same gel, and similar subtype and gp41CT-
related differences were observed (not shown).
doi:10.1371/journal.pone.0161596.g003
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recombinant pairs released by transfected HEK 293T cells and by infected CD4+ T-cells using
a TZM-bl-based single-cycle assay. To this aim, TZM-bl cells were infected with equivalent
amounts of Env and EnvEC recombinants (normalized to p24). As reported in Fig 5A, entry
and the early steps of viral replication in TZM-bl cells of Env and EnvEC viruses produced in
HEK 293T cells were comparable for most virus pairs, regardless of subtype and of the gp41CT
(p>0.05 according to a paired t-test). Likewise, and in keeping with viral propagative infection,
B-EnvEC and B-Env virions produced from CD4+ T-cells comparably infected TZM-bl cells in
the single-round infection assay (Fig 5B). In contrast, entry of 8/12 C-Env viruses produced by
CD4+ T cells was 2 to 5-fold lower than their C-EnvEC counterpart (p = 0.0097) (Fig 5B).
Given that the gp41CT mediates Env incorporation into assembling virions, we investigated
whether differences in Env incorporation underly the lower infectivity of C-Env virions
released by CD4+ T-cells. Unfortunately, no gp120 and very little or no p24 was detectable by
Western Blot (WB) after sucrose gradient centrifugation of C-Env virus supernatants, at all
time points. Therefore, unpurified viral supernatants were used to estimate Env incorporation
by WB. B-Env, B-EnvEC and C-EnvEC viruses incorporated comparable Env levels while
some C-Env viruses contained less Env (e.g. 0677, 1671, 0209) (Fig 5C). These results suggest
that the gp41CT of subtype C affects viral entry, partly by less efficiently mediating incorpo-
ration of Env into virions produced in CD4+ T cells, akin to gp41ΔCT mutants [43, 44, 70, 90,
91]. However, Env in virions did not always correlate with entry of free virions into TZM-bl
cells (e.g. strains 0677, 0487, 0148) (Fig 5B), suggesting that Env incorporation into virions is
Fig 4. The gp41CT of subtype C Envs does not tether virus to CD4+ T-cells.CD4+ T-cells (105 cells/well) were infected with Env or EnvEC
recombinant virus pairs for 5 days, treated with subtilisin or with buffer alone, and virus in each fraction was measured by p24 ELISA. The
amount of p24 that released upon subtilisin-treatment was reported to total p24 (i.e. released in the supernatant+virus attached to the PM).
Three experiments with CD4+ T-cells from different donors are shown (average). Error bars represent standard deviation.
doi:10.1371/journal.pone.0161596.g004
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not the mechanism accounting for lower infectivity of virions or that some tolerance exists in
terms of the number of Env spikes necessary to mediate Env.
Cell-to-cell transmission of C-Env viruses is impaired
We next assessed whether the gp41CT and/or the lower levels of Env in virions affected cell-to-
cell transmission. CD4+ T-cells infected with B- and C-EnvEC and Env recombinant virus
Fig 5. Infectivity of C-Env virions, Env incorporation in virions produced by CD4+ T-cells and cell-to-cell transmission are lessened. (A
and B) Infectivity of virions produced by HEK 293T cells (A) and CD4+ T-cells (B) in a single round TZM-bl assay. TZM-bl cells (2x104 cells/
well) were infected with 2 ng/ml equivalent p24 of Env or EnvEC recombinant viruses produced from HEK 293T cells (A) or from CD4+ T-cells 5
days post infection (B). Viral entry was monitored in cell lysates 48h post-infection. Infections were performed in triplicated wells. The means of
three independent experiments with HEK293T cells and of 4 independent infections with CD4+ T cells from 4 different donors are shown. Error
bars report standard deviationC. Env incorporated in virions produced by CD4+ T-cells. P24 and gp120 in day 5 supernatants of CD4+ T-cells
were quantified byWestern Blot. One representative experiment of two is shown.D and E. Cell-to-cell transmission. CD4+ T-cells were infected
as above with 1 ng/ml equivalent p24. After 48 hours, cell were cocultured with TZM-bl cells in the presence of IDV to avoid any contribution of free
virus. The next morning, MVC and AMD3100 were added to ensure single-round infection. Luciferase in TZM-bl cells was measured after 48
hours. (D) The mean and standard deviation of four independent experiments performed with CD4+ T-cells from four different donors are reported.
(E) The same data is shown for each individual virus pair.
doi:10.1371/journal.pone.0161596.g005
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pairs for 48 hours were co-cultured with TZM-bl cells in the presence of indinavir to avoid any
concomitant infection by free virions. As reported in Fig 5D, transmission of virus pairs faith-
fully recapitulated replication capacity, with transmission of B-EnvEC = B-Env> C-EnvEC>
C-Env viruses (p = 0.0002). Most interestingly, cell-to-cell transmission of C-Env viruses
with poor replication capacity in CD4+ T-cells was considerably lower than that of the corre-
sponding C-EnvEC recombinant while the difference was generally less for C-EnvEC/C-Env
pairs with intermediate replication capacity (Fig 5E). Furthermore, viruses with low levels of
Env (Fig 5C) generally displayed impaired cell-to-cell transmission, showing that decreased
cell-to-cell transmission plays a fundamental role in the lower viral propagative infection of
C-Env viruses. Infection of TZM-bl cells with the supernatant of the CD4+T-cell-TZM-bl co-
culture yielded no signal (not shown), indicating that infection by free virus is negligible in this
set-up.
Subtype C MA decreases viral production, partially rescues viral
replication in CD4+ T-cells but does not rescue infectivity
To assess whether the lower Env incorporation and infectivity of C-Env virions reflected a mis-
match between subtype C gp41CT and subtype B MA, we cloned the MAs of two subtype
strains into the pNL4.3ΔEnv backbone. We selected the MA sequences from one strain with
intermediate replication capacity (strain 1671) and from one strain with poor replication
capacity (strain 0266). With both subtype C MAs, C-Env viral production by transfected HEK
293T cells was lower than with MANL4.3 (p = 0.0091 for MA1671 and p = 0.0106 for MA0266),
despite the MA-gp41CT subtype match (Fig 6A and 6B).
Because of the low viral production with MA0266, CD4+ T-cells could not be infected with
recombinants containing MA0266. In CD4+ T-cells infected with MA1671, MA1671 partially res-
cued viral replication in a donor-dependent fashion: for donor 1, MA1671 rescued replication
fully for 2 Envs and partially for 4 Envs (from 4.3% to 81% of the corresponding C-EnvEC
virus); for donor 2, replication was fully rescued for 5 Envs but not for the other 7; for donor 3,
replication was rescued partially for 6/12 Envs (from 1.6% to 59% replication of the corre-
sponding C-EnvEC virus) and for donor 4, infectivity was rescued for 3 strains and partially
(4.9% and 29.4%) for two strains but not for the remaining 7 strains. Mean p24 in supernatants
was 64.5 ng/ml for C-EnvEC viruses, 9.3 ng/ml for C-Env viruses with MANL4.3 and 17.5 ng/ml
for C-Env viruses with MA1671 (Fig 6C and 6D).
In single round infection assays using virions produced by CD4+ T-cells (normalized to
p24), MA1671 partially rescued infectivity of the autologous C-Env1671 strain, (from 12.6% to
45.5%) but did not rescue infectivity of any other subtype C Env (Fig 6E and 6F). Env incorpo-
ration into virions with MA1671 could not be visualized by WB (not shown), in line with the
low infectivity of these viruses. In cell-to-cell transmission assays, not only was MA1671 unable
to rescue cell-to-cell transmission of all C-Envs viruses, but it further decreased cell-to-cell
transmission compared to the C-Env virus (p = 0.0037, paired t-test), including for the autolo-
gous Env1671 and for the references strains NL4.3 and NLAD8 (Fig 6G and 6H).
Taken together, these data demonstrate that the MA-gp41CT subtype match alone cannot
be held accountable for the low level of incorporation into virions of Envs with subtype C
gp41CT. Rather, they confirm the driver role of MA in viral assembly and cell-to-cell
transmission.
Discussion
The results reported here show that viruses with subtype C gp41CTs have lower replicative
capacity in vitro than viruses with the same Env extracellular domain but a subtype B gp41CT
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 14 / 29
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 15 / 29
in CD4+ T-cells, indicating that polymorphisms in this region directly contribute to viral repli-
cation capacity. Lower replicative capacity was due to both lower infectivity of free viruses pro-
duced by CD4+ T-cells and for the main part, to lower cell-to-cell transmission (Fig 5),
ultimately resulting in decreased viral propagation in CD4+ T-cell cultures (Fig 2A and 2B).
Notably, decreased replication capacity in vitro was cell-type dependent (Fig 5A and 5B), as
subtype C Envs lowered viral replicative capacity in CD4+ T-cells (Fig 2A–2D), but not in
MDMs (Fig 2E–2G). This dichotomy is surprising, considering that gp41CT truncations
inhibit viral replication in both CD4+ T-cells and macrophages [42–44, 70, 90, 91]. One possi-
ble explanation is that the slower assembly process in this cell type, the lesser dependence of
transmission on Env [107] and the retention of virions in PM-related invaginations or in Virus
Containing Compartments [108–112] may compensate for poor virion infectivity in MDMs.
Of note, an earlier report had described lower replication of subtype C primary strains in
MDMs, with a peak at day 21, which never reached the levels of p24 secreted by subtype B
strains [113]. Although the replication kinetics we record for C-Env viruses in CD4+ T-cells
recapitulated those reported by Constantino in MDMs [113], we did not record any difference
in replication kinetics between B-Env and C-Env viruses in infected MDMs (Fig 2E–2G). In
line with this observation, donor-dependent viability was also minimal (not shown). Given
that the recombinant viruses used in our study are based on a subtype B backbone and differ
only by the gp41CT, these different results suggest that viral proteins other than Env account
for the difference in replication capacity between subtypes.
Lower viral infectivity of C-Env viruses in CD4+ T-cells could be associated with lower Env
levels in virions for some strains, particularly for some of the viruses displaying the lowest rep-
licative capacities, such as 0209 and 0266 (Fig 5C). This defect could not be attributed to altered
intracellular localization of Env (not shown). Furthermore, such an observation did not hold
true for all C-Env virions. Alternatively, it is also possible that less favorable Env conformations
governed by the gp41CT [69–73] contribute to infectivity and cell-to-cell transmission. Further
structural studies would be warranted to assess whether Env conformation and/or the number
of Env spikes at the surface of virions varies across subtypes, as such a finding would have
implications for vaccine design. Given that cell-to-cell transmission requires the production of
virus particles with appropriate Env levels [8], it is not surprising that both infection of free
Fig 6. Subtype CMA decreases viral production, only partially rescues viral replication in CD4+ T-
cells but does not restore infectivity. A and B. Production of viruses containing subtype CMA. The
matrix sequences of two subtype C strains with intermediate replication capacity (MA1671) and with poor
replication capacity (MA0266) were cloned into the EnvEC and Env backbones. Recombinant viruses with
subtype C MAs were generated by transfecting HEK 293T cells with these backbones and the corresponding
subtype C EnvEC and Env amplicons from patient samples. p24 produced was measured by ELISA 48 hours
post transfection. At least three independent productions with MANL4.3 and two with MA1671 and MA0266 are
averaged and error bars show standard deviation. Results are shown for all viruses as groups (A) and per
pairs (B).C and D. Replication of C-EnvEC and C-Env recombinant viruses containing subtype C
MA1671 in CD4+ T-cells.CD4+ T-cells were infected with C-EnvEC and C-Env recombinants containing the
MA of NL4.3 or of strain 1671, and p24 was measured in the supernatants 5 days post-infection. The average
and standard deviation of four independent experiments performed with CD4+ T-cells from four different
donors are shown. Results are shown for all viruses as groups (C) and per pairs (D) In (D), relative infectivity
with respect to the corresponding C-EnvEC value is reported. E and F. Infectivity of virions produced by
CD4+ T-cells in a TZM-bl single round assay. TZM-bl cells were infected with supernatants from infected
CD4+ T-cells collected 5 days after infection and adjusted to equivalent p24 contents (2 ng/well). Infection
was monitored 48h post-infection as in Fig 3. The mean of two independent experiments performed with CD4
+ T-cell supernatants from two independent donors are shown and error bars report standard deviation.G
and H. Cell-to-cell transmission of viruses with subtype CMA1671. CD4+ T-cells were infected with
C-EnvEC, C-Env or C-EnvMA1671 viral particles for 40 hours, extensively washed, then co-cultured with TZM-
bl cells for a further 48 hours in the presence of IDV. MVC and AMD3100 were added the next morning. The
mean of two independent experiments is shown. Error bars represent standard deviation. PanelG shows the
same data as panel F detailed for each individual pair.
doi:10.1371/journal.pone.0161596.g006
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virions and cell-to-cell transmission are affected by the low levels of Env incorporated into viri-
ons, nor that lower Env levels in virions preferentially affect cell-to-cell transmission. Cell-to-
cell transmission is the predominant mode of HIV-1 spread in CD4+ T lymphocytes and is
thougt to be 100–1000 times more efficient than infection by cell-free virus [5, 10, 114–118].
Our results showing that cell-to-cell transmission best recapitulates viral replication in CD4
+ T-cells is in line with this observation and with Env:p24 levels. In vivo, cell-to-cell transmis-
sion is belived to play a crucial role due to the tight packing of CD4+ T-cells in lymph nodes
[119]. Because TZM-bl cells express high levels of CD4, the differences reported here might be
underestimated, and it is likely that they might have a much stronger impact in vivo.
A recent study based on sequencial gp41CT truncations dissociated the determinants crucial
for cell-free infection from those permitting cell-to-cell transmission of virus, showing that
large gp41CT truncations (>92 AA) affect cell-to-cell transmission while short gp41CT trun-
cations (<43 AA) are detrimental to cell-free infection [120]. This study also provides evidence
that mutations at the Y802W803 diaromatic motif or at the LL800 dileucine motifs involved in
TIP47 and prohibitin binding respectively [54, 121] affect cell-free virus infection but not cell-
to-cell propagation [120]. In contrast to this report, we found that both cell-free and cell-to-cell
fusion of viruses with subtype C gp41CT were affected, although to different degrees for differ-
ent viral strains (e.g. strains 1671, 0510, 0487, 0148, 0097), and that cell-to-cell transmission
did not compensate for poor free-virion infectivity. One possible explanation for these con-
trasting results could reflect the fact that none of the subtype C variants included in our study
displayed gp41CT truncations nor the LL800RQ mutation engineered by Durham [120]. All
subtype C gp41CT sequences associated with lower viral replication harbored a YW796YL poly-
morphism accompanied by L800F polymorphism (S1 Fig) at the compensatory position
described by Qi et al to restore the interaction of the gp41CT with FIP1C/Rab11a and Env
packaging [55, 66]. Although the polymorphisms observed in subtype C patient sequences dif-
fer from the mutations introduced by Qi et al [66], their role in Env packaging and virus repli-
cation would warrant further investigation.
Replication of C-Env viruses in CD4+ T cells was only very partially rescued by subtype C
MA (Fig 6C and 6D). While MA1671 rescued replication of a virus harboring the autologous
Env1671, it only very partially and not consistently rescued replication of other C-Env viruses
(Fig 6C and 6D). Furthermore, the subtype match between MA and the gp41CT failed to res-
cue infectivity in single-round infections (Fig 6E and 6F) and, surprisingly, further impaired
cell-to-cell transmission of viruses with subtype C Env. These findings differ from a previous
case study documenting the co-evolution between MA and the gp41CT optimizing Env incor-
poration [91]. We also found that subtype C MA further decreased (MA1671) or nearly abro-
gated (MA0266) viral production (Fig 6A and 6B), in sharp contrast with Beaumont’s report
[91]. In the case reported by Beaumont, poor Env incorporation was consequent to a trunca-
tion of LLP-1 [91], while in our study none of the gp41CT patient sequences harbored trunca-
tions in LLP-1 or in LLP-2/3 (S1 Fig), which may limit the rescue potential by MA. Patients
0266 and 1671 had comparable viral loads and CD4 counts, had been infected for a comparable
number of years, and displayed no particular mutation in the MA sequence (S2 Fig), which
could explain such drastic differences. Our findings therefore imply that the lower infectivity of
C-Env virions is not due to the subtype match with MA but rather reflects intrinsic properties
of the gp41CT and that other mechanisms must operate. Further studies will be needed to
identify them. They also further underscore that the viral MA is the main driver of viral assem-
bly and replication capacity.
Intracellular viral protein contents 5-days post infection were low and mature forms of Gag
were absent in cultures infected with C-Env viruses (Fig 3A). While lower viral protein con-
tents did not correlate with β-actin expression, arguing against cell-death as a cause of lower
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viral production, nor with impaired viral release (Fig 4), it most likely reflects the low replica-
tion capacity and lack of spread of C-Env viruses in CD4+ T-cells. It is also unlikely that low
viral protein contents in cell lysates reflect lower protein expression, given that at early time
points (40 hours post infection) intracellular viral protein levels were comparable (Fig 3B).
This conclusion is reinforced by the observation that Envs with subtype B or subtype C
gp41CTs do not trigger any transcription from the LTR nor activate NF-κB (Beraud and
Lemaire, submitted), in contrast to previous reports by other groups [83–86].
In our experimental design, recombination between the Env or EnvEC backbone and the
Env or EnvEC amplicon occurs within Vpu, although it is not known where the breakpoint
occurs. Vpu is a frequent breakpoint for inter-subtype recombination in vivo [122] and may
impact its efficiency in down modulating BST-2 [122, 123] and viruses with recombinant BC
[123] and BF [122] Vpu are moderately more efficient than subtype B or CB recombinant Vpu
in down-modulating BST-2. In our study, viral release tended to be higher for viruses with sub-
type C gp41CT than for their isogenic counterpart with the gp41CT of NL4.3 (Fig 4). More-
over, 5 days post infection, mature Gag products were lower in CD4+ T-cell lysates infected
with C-Env viruses (Fig 3), which is inconsistent with a defect in viral release [124].
Polymorphisms in the gp41CT also overlap the second exon of Tat and Rev. With the
exception of one subtype B Tat, which displayed the same STOP codon as HXB2, no premature
STOP codon was present. Tat was highly conserved, particularly the basic AA, except for a
K13E mutation in the second exon in many, but not all, subtype C Tat sequences (S3A Fig). A
defect in Tat function would have impacted luciferase induction in TZM-bl cells, and is thus
not consistent with the comparable signal induced by HEK293T supernatants. Rev sequence
inspection highlighted that subtype C sequences were 8 AA shorter than subtype B, and two
(those which did not contain the 7 AA insertion) were 15 AA shorter. Amino acids involved in
Rev multimerization (Ile52, Ile55 and Ile59) as well as the Arginine-rich RNA-binding effector
domain were highly conserved. The Leucine rich effector domain displayed two L⇾I muta-
tions, and was not affected by the 7 AA insertion. The Nuclear Export Signal was highly con-
served and was not affected by the 7 AA insertion, which lies downstream (S3B Fig).
Furthermore, a Rev-related defect in Env mRNA export is not consistent with the higher sub-
type C Env expression levels in infected CD4+ T-cells (Fig 3) nor with the similar viral produc-
tion by HEK293T cells recorded for all recombinants (not shown). Last but not least, in
macrophages, where Rev plays a crucial role, no difference in replicaton was recorded, suggest-
ing that the observed impact reflects a gp41CT-mediated effect rather than a Tat-related tran-
scriptional defect or Rev-dependent impaired viral protein export.
Why subtype C strains would have evolved to reach lower replication levels, and how poly-
morphisms in this region would benefit the virus remains to be established. One possibility is
that polymorphisms in this region reduce the immunogenic or cytopathic potential of Env, and
therefore represent an advantage in terms of immune escape thereby favoring the long term
persistence of infection. In macaques infected with SIVmac bearing a Y721xxL mutation that
increased Env expression, viral load was controlled by the immune response until reversion of
the mutation [125]. Env is cytopathic, pro-apoptotic and is targeted by the humoral immune
response [126–128]. In our experiments, CD4+ T cell death was related to the level of infectiv-
ity rather than to a specific Env or Env gp41CT (data not shown), supporting this hypothesis.
Higher Env tolerance, delayed replication kinetics, decreased Env in virions and immune
escape could explain why subtype C strains account for over half of worldwide infections.
In conclusion, our results show that polymorphisms in the gp41CT of subtype C decrease
viral infectivity and cell-to-cell transmission, thereby impairing viral propagative infection in
CD4+ T-cells, most likely by enabling less Env incorporation into virions. Subtype C MA only
partially rescued viral replication capacity, in a strain-dependent manner, emphasizing its
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crucial role as a driver of viral assembly. One compensatory mechanism evolved by subtype C
strains could involve higher Env levels and tolerance, favoring the long term persistence of
infection, particularly via macrophages. Other compensatory mechanisms may exist elsewhere
in the subtype C viral genome, such as intrinsic properties of MA or promoter-related replica-
tion advantages [129, 130] linked to AP-1 and the third NF-κB site typically found in the LTR
of subtype C strains [130–132]. These findings may have consequences for vaccine design as
they imply subtype-dependent differences.
Supporting Information
S1 Fig. Alignment of subtype B and subtype C gp41CT sequences against the NL4.3 refer-
ence. The patient gp41CT were sequenced from the same env amplicons used to produce Env-
recombinant viruses to avoid PCR-selection biases. Sequencing was performed using BigDye
Terminator v3.1 dye on a Applied Biosystems 3500 xL DX genetic analyzer (Applied Biosys-
tems Europe BV, Belgium), with sense primer AV326 and reverse primer AV331 [104].
Sequence alignments were performed by CLCMain Workbench v7.5 Software (Aarhus, Den-
mark). The domains involved in Env trafficking (Y712SPL, C-terminal LL856 and Y802W803,)
are boxed (yellow and green) and topped with a star, the PT/RRIR sequence (blue) and the three
immunogenic epitopes are boxed (pink). The locations of the LLP α-helices are assigned based
on the NL4.3 reference sequence. gp41CT sequence analysis highlights that subtype B strains
closely resembles the NL4.3 reference, whereas subtype C harbors a number of specific poly-
morphisms. The main Y712SPL endocytic motif (yellow box), the Y802W803 diaromatic motif
(green box) as well as all but one Arg spanning the LLP α-helices, the Arg-rich PT/RRIR motif
(blue box) and Cys residues within LLP-1 are highly conserved in all samples, underscoring
their chief role in Env intracellular traffic and incorporation into virions. The second Y768XXL
motif is 100% conserved as well. Notably, the C-terminal dileucine motif LL856 within LLP-1
(yellow box) is replaced by LQ856 in 9/12 subtype C Envs (8 pure, and 1 LL/LQ856 mixtures).
Other subtype C-specific polymorphisms involve the dileucine motifs spanning the gp41CT
LLP-2/3 α-helices (LLL776!FIL776 and LL800!LV800), polar/charged residues (WN798!GS798,
SQ805!GL805, N809!K, NA817!DT817 and R853!A in LLP-1) and a conserved seven AA
insertion (SSLRGLQ, 2 α-helical turns) between R787 and R788 (10/12 subtype C Envs). The Ken-
nedy sequence contains a number of subtype-specific mutations, including a R!Q and D!N/S/
G mutations in the E739RDRD743 epitope.
(TIF)
S2 Fig. Sequence alignment of subtype C strain MA against the NL4.3 reference.MA was
sequenced from the same RNA extracted and used for Env amplification. A cDNA was synthe-
sized from 10 μl RNA in a one-step PCR reaction using forward primer KVL064 and reverse
primer KVL079 [133] as described in [133]. Two microliters of cDNA were further amplified
using Forward primer KVL066 and Reverse primer KVL080 [133]. Amplicon size and quality
was verified by agarose gel electrophoresis and sequenced using primers KVL066, KVL080,
KVL081 and GA1 [133]. Sequences were aligned and analyzed using the CLC Bio Main Work-
bench 6.82 software. The consensus sequence logos were generated with WebLogo3.3. All resi-
dues known to be involved in the interaction of MA with Env and in Env incorporation into
virions (i.e. residues L8 [8, 81], L12, L30, V34 [37, 43], K32 [41], L49 [134], E99 [135], the basic
domain of MA (AA 17–21) [103]) were 100% conserved in all subtype C strains, with the
exception of S8 [8, 81], which was replaced by an Arg in all subtype C sequences, and of residue
L30, which was conserved in 8/12 of strains and was replaced by a Met in the remaining 4
viruses, but could not be associated with lower replication levels or Env incorporation. MA
compensatory mutations V34I [37, 43, 91] and Q62R [136] were consistently absent from
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subtype C MAs. S9R was present in 11/12 subtype C strains and S9K in one, regardless of repli-
cation capacity, and the role of this specific polymorphism without a mutation at L8 is not
known. Basic residues 17–21 mediating MA interaction with Env [137] [38, 40–42, 44, 70, 138]
or AA involved in p55Gag trafficking via adaptor proteins (Y132 and V135 at the MA/CA junc-
tion) [49, 68, 139, 140] were also conserved. AA involved in myristylation (AA1-6 and G10), in
the myristyl switch (H89) or in p55Gag targeting to the PM (AA 84–89) [141–146] were con-
served, and E12 hosted a Lysine, as reported for HIV-2 [146]. Other subtype C specific poly-
morphisms were generally found in all sequences and we could not identify polymorphisms
that were only present in strains with very poor replication capacity or that were associated
with the presence of subtype C polymorphisms within the gp41CT.
(TIF)
S3 Fig. Sequence alignment of subtype B and C Tat and Rev sequences against the NL4.3
reference. Tat (A) and Rev (B) exon II sequence alignments. The second exon of Tat and of
Rev overlap the gp41CT. Tat and Rev sequences were aligned against the NL4.3 reference using
the CLC Bio Main Workbench v.7.5 software. Tat was highly conserved, particularly the basic
AA, with the exception of a K13 E mutation in the second exon in many, but not all, subtype C
Tat sequences. Rev subtype C sequences had a CAA (Gln) TAA (STOP) mutation matching
the HXB2 premature end (marked with a ). Therefore, subtype C Rev proteins were 8 AA
shorter than subtype B, and two (those which did not contain the 7 AA insertion) were 15 AA
shorter. Amino acids involved in Rev multimerization (I52, I55 and I59) and the Arginine-rich
RNA-binding effector domain were generally conserved. The Nuclear Export Signal displayed
two LI mutations and was not affected by the 7 AA insertion.
(TIF)
Acknowledgments
This work was supported by the Luxembourg Ministry of Research and Education Grants
#MESR LRTV20100604 and REC-LRTV10131106. ESS, MM and CB were supported by PhD
fellowships from the Fonds National de la Recherche (AFR grants #PHD-09-115, #PHD-08-
074 and AFR-6012272 respectively).
The authors are deeply grateful to the patients who participated in this study, to Céline
Hoffman for help and support with confocal microscopy staining, to Julie Mathu for help with
WB and to Nicolas Sauvageot for help with statistical analyses.
Ethical clearance




Formal analysis: ESS MMDPB.
Funding acquisition: DPB.
Investigation: ESS MMML CB CM JYS AR GI.
Methodology: DPB ESS MMML.
Project administration: DPB.
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 20 / 29
Resources: DPB JCS CSD.
Supervision: DPB.
Validation: ESS MMML DPB.
Visualization: ESS MMDPB.
Writing – original draft: ESS MMDPB.
Writing – review & editing: ESS DPB.
References
1. Blanco J, Bosch B, Fernandez-Figueras MT, Barretina J, Clotet B, Este JA. High level of coreceptor-
independent HIV transfer induced by contacts between primary CD4 T cells. The Journal of biological
chemistry. 2004; 279(49):51305–14. Epub 2004/09/17. doi: 10.1074/jbc.M408547200 M408547200
[pii]. PMID: 15371410.
2. Chen P, Hubner W, Spinelli MA, Chen BK. Predominant mode of human immunodeficiency virus
transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological
synapses. Journal of virology. 2007; 81(22):12582–95. Epub 2007/08/31. JVI.00381-07 [pii] doi: 10.
1128/JVI.00381-07 PMID: 17728240; PubMed Central PMCID: PMC2169007.
3. Hubner W, McNerney GP, Chen P, Dale BM, Gordon RE, Chuang FY, et al. Quantitative 3D video
microscopy of HIV transfer across T cell virological synapses. Science. 2009; 323(5922):1743–7.
Epub 2009/03/28. 323/5922/1743 [pii] doi: 10.1126/science.1167525 PMID: 19325119; PubMed Cen-
tral PMCID: PMC2756521.
4. Ruggiero E, Bona R, Muratori C, Federico M. Virological consequences of early events following cell-
cell contact between human immunodeficiency virus type 1-infected and uninfected CD4+ cells. Jour-
nal of virology. 2008; 82(16):7773–89. Epub 2008/05/30. JVI.00695-08 [pii] doi: 10.1128/JVI.00695-
08 PMID: 18508887; PubMed Central PMCID: PMC2519596.
5. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient human immunodeficiency
virus replication in mobile lymphocytes. Journal of virology. 2007; 81(2):1000–12. Epub 2006/11/03.
JVI.01629-06 [pii] doi: 10.1128/JVI.01629-06 PMID: 17079292; PubMed Central PMCID:
PMC1797449.
6. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nano-
tubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission.
Nat Cell Biol. 2008; 10(2):211–9. Epub 2008/01/15. ncb1682 [pii] doi: 10.1038/ncb1682 PMID:
18193035.
7. Haller C, Fackler OT. HIV-1 at the immunological and T-lymphocytic virological synapse. Biol Chem.
2008; 389(10):1253–60. Epub 2008/08/21. doi: 10.1515/BC.2008.143 10.1515/BC.2008.143 [pii].
PMID: 18713012.
8. Monel B, Beaumont E, Vendrame D, Schwartz O, Brand D, Mammano F. HIV cell-to-cell transmission
requires the production of infectious virus particles and does not proceed through env-mediated fusion
pores. Journal of virology. 2012; 86(7):3924–33. Epub 2012/01/20. doi: 10.1128/JVI.06478-11 PMID:
22258237; PubMed Central PMCID: PMC3302491.
9. Jolly C, Sattentau QJ. Retroviral spread by induction of virological synapses. Traffic. 2004; 5(9):643–
50. Epub 2004/08/07. doi: 10.1111/j.1600-0854.2004.00209.x TRA209 [pii]. PMID: 15296489.
10. Sattentau QJ. Cell-to-Cell Spread of Retroviruses. Viruses. 2010; 2(6):1306–21. Epub 2010/06/01.
doi: 10.3390/v2061306 PMID: 21994681; PubMed Central PMCID: PMC3185708.
11. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Sci-
ence. 1998; 280(5371):1884–8. Epub 1998/06/25. PMID: 9632381.
12. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, GartenW. Inhibition of furin-mediated cleav-
age activation of HIV-1 glycoprotein gp160. Nature. 1992; 360(6402):358–61. doi: 10.1038/360358a0
PMID: 1360148.
13. Mao Y, Wang L, Gu C, Herschhorn A, Xiang SH, Haim H, et al. Subunit organization of the mem-
brane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol. 2012; 19(9):893–9. Epub 2012/
08/07. doi: 10.1038/nsmb.2351 PMID: 22864288; PubMed Central PMCID: PMC3443289.
14. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) anti-
gen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312(5996):763–
7. PMID: 6096719.
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 21 / 29
15. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the
AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986; 47(3):333–48.
PMID: 3094962.
16. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, HendricksonWA. Structure of an HIV gp120
envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature.
1998; 393(6686):648–59. PMID: 9641677.
17. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a
RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Sci-
ence. 1996; 272(5270):1955–8. PMID: 8658171.
18. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor
for primary isolates of HIV-1. Nature. 1996; 381(6584):661–6. PMID: 8649511.
19. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a
seven-transmembrane, G protein-coupled receptor. Science. 1996; 272(5263):872–7. PMID:
8629022.
20. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+
cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996; 381(6584):667–73. PMID:
8649512.
21. Freed EO, Myers DJ, Risser R. Characterization of the fusion domain of the human immunodeficiency
virus type 1 envelope glycoprotein gp41. Proceedings of the National Academy of Sciences of the
United States of America. 1990; 87(12):4650–4. PMID: 2191297; PubMed Central PMCID:
PMC54174.
22. Bosch ML, Earl PL, Fargnoli K, Picciafuoco S, Giombini F, Wong-Staal F, et al. Identification of the
fusion peptide of primate immunodeficiency viruses. Science. 1989; 244(4905):694–7. PMID:
2541505.
23. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain
from HIV-1 gp41. Nature. 1997; 387(6631):426–30. PMID: 9163431.
24. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein.
Cell. 1997; 89(2):263–73. PMID: 9108481.
25. Doms RW, Moore JP. HIV-1 membrane fusion: targets of opportunity. J Cell Biol. 2000; 151(2):F9–14.
PMID: 11038194.
26. Brasseur R, Vandenbranden M, Cornet B, Burny A, Ruysschaert JM. Orientation into the lipid bilayer
of an asymmetric amphipathic helical peptide located at the N-terminus of viral fusion proteins. Bio-
chim Biophys Acta. 1990; 1029(2):267–73. PMID: 2245211.
27. Blumenthal R, Durell S, Viard M. HIV entry and envelope glycoprotein-mediated fusion. The Journal
of biological chemistry. 2012; 287(49):40841–9. doi: 10.1074/jbc.R112.406272 PMID: 23043104;
PubMed Central PMCID: PMC3510787.
28. Hunter E, Swanstrom R. Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol. 1990;
157:187–253. Epub 1990/01/01. PMID: 2203609.
29. Miller MA, Garry RF, Jaynes JM, Montelaro RC. A structural correlation between lentivirus transmem-
brane proteins and natural cytolytic peptides. AIDS research and human retroviruses. 1991; 7
(6):511–9. PMID: 1657072.
30. Steckbeck JD, Craigo JK, Barnes CO, Montelaro RC. Highly conserved structural properties of the C-
terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: impli-
cations for functions in viral replication. The Journal of biological chemistry. 2011; 286(31):27156–66.
Epub 2011/06/11. M111.258855 [pii] doi: 10.1074/jbc.M111.258855 PMID: 21659530; PubMed Cen-
tral PMCID: PMC3149309.
31. Checkley MA, Luttge BG, Freed EO. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incor-
poration. J Mol Biol. 2011; 410(4):582–608. Epub 2011/07/19. doi: 10.1016/j.jmb.2011.04.042 PMID:
21762802; PubMed Central PMCID: PMC3139147.
32. Postler TS, Desrosiers RC. The Tale of the Long Tail: the Cytoplasmic Domain of HIV-1 gp41. Journal
of virology. 2012. Epub 2012/10/19. doi: 10.1128/JVI.02053-12 PMID: 23077317.
33. Steckbeck JD, Kuhlmann AS, Montelaro RC. C-terminal tail of human immunodeficiency virus gp41:
functionally rich and structurally enigmatic. J Gen Virol. 2012. Epub 2012/10/20. doi: 10.1099/vir.0.
046508–0 PMID: 23079381.
34. Santos da Silva E, Mulinge M, Perez Bercoff D. The frantic play of the concealed HIV envelope cyto-
plasmic tail. Retrovirology. 2013; 10(1):54. Epub 2013/05/28. doi: 10.1186/1742-4690-10-54 PMID:
23705972.
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 22 / 29
35. Steckbeck JD, Kuhlmann AS, Montelaro RC. Structural and functional comparisons of retroviral enve-
lope protein C-terminal domains: still much to learn. Viruses. 2014; 6(1):284–300. doi: 10.3390/
v6010284 PMID: 24441863; PubMed Central PMCID: PMCPMC3917443.
36. Gonzalez SA, Burny A, Affranchino JL. Identification of domains in the simian immunodeficiency virus
matrix protein essential for assembly and envelope glycoprotein incorporation. Journal of virology.
1996; 70(9):6384–9. Epub 1996/09/01. PMID: 8709267; PubMed Central PMCID: PMC190665.
37. Freed EO, Martin MA. Domains of the human immunodeficiency virus type 1 matrix and gp41 cyto-
plasmic tail required for envelope incorporation into virions. Journal of virology. 1996; 70(1):341–51.
Epub 1996/01/01. PMID: 8523546; PubMed Central PMCID: PMC189823.
38. Dubay JW, Roberts SJ, Hahn BH, Hunter E. Truncation of the human immunodeficiency virus type 1
transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. Journal of virology. 1992; 66
(11):6616–25. Epub 1992/11/01. PMID: 1357190; PubMed Central PMCID: PMC240157.
39. Yu X, Matsuda Z, Yu QC, Lee TH, Essex M. Vpx of simian immunodeficiency virus is localized primar-
ily outside the virus core in mature virions. Journal of virology. 1993; 67(7):4386–90. PMID: 8510227.
40. Cosson P. Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J. 1996; 15
(21):5783–8. Epub 1996/11/01. PMID: 8918455; PubMed Central PMCID: PMC452325.
41. Lee YM, Tang XB, Cimakasky LM, Hildreth JE, Yu XF. Mutations in the matrix protein of human immu-
nodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glyco-
proteins in CD4+ T lymphocytes. Journal of virology. 1997; 71(2):1443–52. Epub 1997/02/01. PMID:
8995670; PubMed Central PMCID: PMC191201.
42. Murakami T, Freed EO. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner
for HIV-1 envelope glycoprotein incorporation into virions. Proceedings of the National Academy of
Sciences of the United States of America. 2000; 97(1):343–8. Epub 2000/01/05. PMID: 10618420;
PubMed Central PMCID: PMC26665.
43. Murakami T, Freed EO. Genetic evidence for an interaction between human immunodeficiency virus
type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. Journal of virology. 2000; 74(8):3548–54.
Epub 2000/03/23. PMID: 10729129; PubMed Central PMCID: PMC111863.
44. Piller SC, Dubay JW, Derdeyn CA, Hunter E. Mutational analysis of conserved domains within the
cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorpo-
ration and infectivity. Journal of virology. 2000; 74(24):11717–23. Epub 2000/11/23. PMID:
11090171; PubMed Central PMCID: PMC112454.
45. Hourioux C, Brand D, Sizaret PY, Lemiale F, Lebigot S, Barin F, et al. Identification of the glycoprotein
41(TM) cytoplasmic tail domains of human immunodeficiency virus type 1 that interact with Pr55Gag
particles. AIDS research and human retroviruses. 2000; 16(12):1141–7. Epub 2000/08/24. doi: 10.
1089/088922200414983 PMID: 10954889.
46. Freed EO, Martin MA. Virion incorporation of envelope glycoproteins with long but not short cyto-
plasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency
virus type 1 matrix. Journal of virology. 1995; 69(3):1984–9. Epub 1995/03/01. PMID: 7853546;
PubMed Central PMCID: PMC188822.
47. Mammano F, Kondo E, Sodroski J, Bukovsky A, Gottlinger HG. Rescue of human immunodeficiency
virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. Journal
of virology. 1995; 69(6):3824–30. Epub 1995/06/01. PMID: 7745730; PubMed Central PMCID:
PMC189100.
48. Wyma DJ, Kotov A, Aiken C. Evidence for a stable interaction of gp41 with Pr55(Gag) in immature
human immunodeficiency virus type 1 particles. Journal of virology. 2000; 74(20):9381–7. PMID:
11000206.
49. Camus G, Segura-Morales C, Molle D, Lopez-Verges S, Begon-Pescia C, Cazevieille C, et al. The
clathrin adaptor complex AP-1 binds HIV-1 and MLV Gag and facilitates their budding. Mol Biol Cell.
2007; 18(8):3193–203. Epub 2007/06/01. doi: 10.1091/mbc.E06-12-1147 PMID: 17538020; PubMed
Central PMCID: PMC1949356.
50. Blot G, Janvier K, Le Panse S, Benarous R, Berlioz-Torrent C. Targeting of the human immunodefi-
ciency virus type 1 envelope to the trans-Golgi network through binding to TIP47 is required for env
incorporation into virions and infectivity. Journal of virology. 2003; 77(12):6931–45. Epub 2003/05/28.
PMID: 12768012; PubMed Central PMCID: PMC156179.
51. Murray JL, Mavrakis M, McDonald NJ, Yilla M, Sheng J, Bellini WJ, et al. Rab9 GTPase is required for
replication of human immunodeficiency virus type 1, filoviruses, and measles virus. Journal of virol-
ogy. 2005; 79(18):11742–51. Epub 2005/09/06. doi: 10.1128/JVI.79.18.11742–11751.2005 PMID:
16140752; PubMed Central PMCID: PMC1212642.
52. Lopez-Verges S, Camus G, Blot G, Beauvoir R, Benarous R, Berlioz-Torrent C. Tail-interacting pro-
tein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 23 / 29
virions. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103
(40):14947–52. Epub 2006/09/28. doi: 10.1073/pnas.0602941103 PMID: 17003132; PubMed Central
PMCID: PMC1595456.
53. Lambele M, Labrosse B, Roch E, Moreau A, Verrier B, Barin F, et al. Impact of natural polymorphism
within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribu-
tion of envelope glycoproteins and viral assembly. Journal of virology. 2007; 81(1):125–40. PMID:
17050592.
54. Bauby H, Lopez-Verges S, Hoeffel G, Delcroix-Genete D, Janvier K, Mammano F, et al. TIP47 is
required for the production of infectious HIV-1 particles from primary macrophages. Traffic. 2010; 11
(4):455–67. Epub 2010/01/15. TRA1036 [pii] doi: 10.1111/j.1600-0854.2010.01036.x PMID:
20070608.
55. Qi M, Williams JA, Chu H, Chen X, Wang JJ, Ding L, et al. Rab11-FIP1C and Rab14 direct plasma
membrane sorting and particle incorporation of the HIV-1 envelope glycoprotein complex. PLoS
Pathog. 2013; 9(4):e1003278. Epub 2013/04/18. doi: 10.1371/journal.ppat.1003278 PMID:
23592992; PubMed Central PMCID: PMC3616983.
56. Checkley MA, Luttge BG, Mercredi PY, Kyere SK, Donlan J, Murakami T, et al. Reevaluation of the
requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.
Journal of virology. 2013; 87(6):3561–70. Epub 2013/01/18. doi: 10.1128/JVI.03299-12 PMID:
23325685; PubMed Central PMCID: PMC3592152.
57. Rowell JF, Stanhope PE, Siliciano RF. Endocytosis of endogenously synthesized HIV-1 envelope
protein. Mechanism and role in processing for association with class II MHC. J Immunol. 1995; 155
(1):473–88. Epub 1995/07/01. PMID: 7602119.
58. Bultmann A, Muranyi W, Seed B, Haas J. Identification of two sequences in the cytoplasmic tail of the
human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression. Jour-
nal of virology. 2001; 75(11):5263–76. Epub 2001/05/03. doi: 10.1128/JVI.75.11.5263–5276.2001
PMID: 11333908; PubMed Central PMCID: PMC114932.
59. LaBranche CC, Sauter MM, Haggarty BS, Vance PJ, Romano J, Hart TK, et al. A single amino acid
change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule
increases envelope glycoprotein expression on infected cells. Journal of virology. 1995; 69(9):5217–
27. Epub 1995/09/01. PMID: 7636963; PubMed Central PMCID: PMC189351.
60. Ohno H. Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science.
1995; 269:1872–5. PMID: 7569928
61. Ohno H, Aguilar RC, Fournier MC, Hennecke S, Cosson P, Bonifacino JS. Interaction of endocytic
signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain
family. Virology. 1997; 238(2):305–15. Epub 1997/12/24. S0042-6822(97)98839-5 [pii] doi: 10.1006/
viro.1997.8839 PMID: 9400603.
62. Ohno H, Fournier MC, Poy G, Bonifacino JS. Structural determinants of interaction of tyrosine-based
sorting signals with the adaptor medium chains. The Journal of biological chemistry. 1996; 271
(46):29009–15. Epub 1996/11/15. PMID: 8910552.
63. Wyss S, Berlioz-Torrent C, Boge M, Blot G, Honing S, Benarous R, et al. The highly conserved C-ter-
minal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope
glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter]. Journal
of virology. 2001; 75(6):2982–92. Epub 2001/02/27. doi: 10.1128/JVI.75.6.2982–2992.2001 PMID:
11222723; PubMed Central PMCID: PMC115924.
64. Byland R, Vance PJ, Hoxie JA, Marsh M. A conserved dileucine motif mediates clathrin and AP-2-
dependent endocytosis of the HIV-1 envelope protein. Mol Biol Cell. 2007; 18(2):414–25. Epub 2006/
11/17. E06-06-0535 [pii] doi: 10.1091/mbc.E06-06-0535 PMID: 17108326; PubMed Central PMCID:
PMC1783771.
65. Groppelli E, Len AC, Granger LA, Jolly C. Retromer regulates HIV-1 envelope glycoprotein trafficking
and incorporation into virions. PLoS Pathog. 2014; 10(10):e1004518. doi: 10.1371/journal.ppat.
1004518 PMID: 25393110; PubMed Central PMCID: PMCPMC4231165.
66. Qi M, Chu H, Chen X, Choi J, Wen X, Hammonds J, et al. A tyrosine-based motif in the HIV-1 enve-
lope glycoprotein tail mediates cell-type- and Rab11-FIP1C-dependent incorporation into virions. Pro-
ceedings of the National Academy of Sciences of the United States of America. 2015; 112(24):7575–
80. doi: 10.1073/pnas.1504174112 PMID: 26034275; PubMed Central PMCID: PMCPMC4475960.
67. Egan MA, Carruth LM, Rowell JF, Yu X, Siliciano RF. Human immunodeficiency virus type 1 envelope
protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic
domain of gp41 is suppressed in the presence of the Pr55gag precursor protein. Journal of virology.
1996; 70(10):6547–56. Epub 1996/10/01. PMID: 8794289; PubMed Central PMCID: PMC190695.
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 24 / 29
68. Berlioz-Torrent C, Shacklett BL, Erdtmann L, Delamarre L, Bouchaert I, Sonigo P, et al. Interactions of
the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of
the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glyco-
proteins. Journal of virology. 1999; 73(2):1350–61. Epub 1999/01/09. PMID: 9882340; PubMed Cen-
tral PMCID: PMC103959.
69. Edwards TG, Wyss S, Reeves JD, Zolla-Pazner S, Hoxie JA, Doms RW, et al. Truncation of the cyto-
plasmic domain induces exposure of conserved regions in the ectodomain of human immunodefi-
ciency virus type 1 envelope protein. Journal of virology. 2002; 76(6):2683–91. Epub 2002/02/28.
PMID: 11861835; PubMed Central PMCID: PMC135967.
70. Kalia V, Sarkar S, Gupta P, Montelaro RC. Rational site-directed mutations of the LLP-1 and LLP-2
lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1
gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation.
Journal of virology. 2003; 77(6):3634–46. PMID: 12610139.
71. Wyss S, Dimitrov AS, Baribaud F, Edwards TG, Blumenthal R, Hoxie JA. Regulation of human immu-
nodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41
cytoplasmic tail. Journal of virology. 2005; 79(19):12231–41. PMID: 16160149.
72. Bhakta SJ, Shang L, Prince JL, Claiborne DT, Hunter E. Mutagenesis of tyrosine and di-leucine motifs
in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity. Ret-
rovirology. 2011; 8:37. Epub 2011/05/17. 1742-4690-8-37 [pii] doi: 10.1186/1742-4690-8-37 PMID:
21569545; PubMed Central PMCID: PMC3117779.
73. Emerson V, Haller C, Pfeiffer T, Fackler OT, Bosch V. Role of the C-terminal domain of the HIV-1 gly-
coprotein in cell-to-cell viral transmission between T lymphocytes. Retrovirology. 2010; 7:43. Epub
2010/05/13. 1742-4690-7-43 [pii] doi: 10.1186/1742-4690-7-43 PMID: 20459872; PubMed Central
PMCID: PMC2875203.
74. Owens RJ, Dubay JW, Hunter E, Compans RW. Human immunodeficiency virus envelope protein
determines the site of virus release in polarized epithelial cells. Proceedings of the National Academy
of Sciences of the United States of America. 1991; 88(9):3987–91. Epub 1991/05/01. PMID:
2023946; PubMed Central PMCID: PMC51578.
75. Lodge R, Gottlinger H, Gabuzda D, Cohen EA, Lemay G. The intracytoplasmic domain of gp41 medi-
ates polarized budding of human immunodeficiency virus type 1 in MDCK cells. Journal of virology.
1994; 68(8):4857–61. Epub 1994/08/01. PMID: 8035484; PubMed Central PMCID: PMC236425.
76. Lodge R, Lalonde JP, Lemay G, Cohen EA. The membrane-proximal intracytoplasmic tyrosine resi-
due of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells.
EMBO J. 1997; 16(4):695–705. Epub 1997/02/17. doi: 10.1093/emboj/16.4.695 PMID: 9049299;
PubMed Central PMCID: PMC1169671.
77. Deschambeault J, Lalonde JP, Cervantes-Acosta G, Lodge R, Cohen EA, Lemay G. Polarized
human immunodeficiency virus budding in lymphocytes involves a tyrosine-based signal and favors
cell-to-cell viral transmission. Journal of virology. 1999; 73(6):5010–7. Epub 1999/05/11. PMID:
10233963; PubMed Central PMCID: PMC112545.
78. Lee SF, Wang CT, Liang JY, Hong SL, Huang CC, Chen SS. Multimerization potential of the cyto-
plasmic domain of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41. The
Journal of biological chemistry. 2000; 275(21):15809–19. Epub 2000/04/05. doi: 10.1074/jbc.
M000601200 M000601200 [pii]. PMID: 10747937.
79. Zhu Y, Lu L, Chao L, Chen YH. Important changes in biochemical properties and function of mutated
LLP12 domain of HIV-1 gp41. Chemical biology & drug design. 2007; 70(4):311–8. Epub 2007/09/14.
doi: 10.1111/j.1747-0285.2007.00564.x PMID: 17850282.
80. Chojnacki J, Staudt T, Glass B, Bingen P, Engelhardt J, Anders M, et al. Maturation-dependent HIV-1
surface protein redistribution revealed by fluorescence nanoscopy. Science. 2012; 338(6106):524–8.
Epub 2012/11/01. doi: 10.1126/science.1226359 PMID: 23112332.
81. Muranyi W, Malkusch S, Muller B, Heilemann M, Krausslich HG. Super-resolution microscopy reveals
specific recruitment of HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-
terminal tail. PLoS Pathog. 2013; 9(2):e1003198. Epub 2013/03/08. doi: 10.1371/journal.ppat.
1003198 PMID: 23468635; PubMed Central PMCID: PMC3585150.
82. Roy NH, Chan J, Lambele M, Thali M. Clustering and Mobility of HIV-1 Env at Viral Assembly Sites
Predict Its Propensity To Induce Cell-Cell Fusion. Journal of virology. 2013; 87(13):7516–25. Epub
2013/05/03. doi: 10.1128/JVI.00790-13 PMID: 23637402.
83. Postler TS, Desrosiers RC. The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-kap-
paB activation through TGF-beta-activated kinase 1. Cell Host Microbe. 2012; 11(2):181–93. Epub
2012/02/22. doi: 10.1016/j.chom.2011.12.005 PMID: 22341466; PubMed Central PMCID:
PMC3285415.
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 25 / 29
84. Zhang H, Wang L, Kao S, Whitehead IP, Hart MJ, Liu B, et al. Functional interaction between the cyto-
plasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF. Curr Biol. 1999; 9(21):1271–4.
Epub 1999/11/11. PMID: 10556093.
85. Wang L, Zhang H, Solski PA, Hart MJ, Der CJ, Su L. Modulation of HIV-1 replication by a novel RhoA
effector activity. J Immunol. 2000; 164(10):5369–74. Epub 2000/05/09. PMID: 10799900.
86. Blot G, Lopez-Verges S, Treand C, Kubat NJ, Delcroix-Genete D, Emiliani S, et al. Luman, a new part-
ner of HIV-1 TMgp41, interferes with Tat-mediated transcription of the HIV-1 LTR. J Mol Biol. 2006;
364(5):1034–47. doi: 10.1016/j.jmb.2006.09.080 PMID: 17054986.
87. Wilk T, Pfeiffer T, Bosch V. Retained in vitro infectivity and cytopathogenicity of HIV-1 despite trunca-
tion of the C-terminal tail of the env gene product. Virology. 1992; 189(1):167–77. PMID: 1604808.
88. Akari H, Fukumori T, Adachi A. Cell-dependent requirement of human immunodeficiency virus type 1
gp41 cytoplasmic tail for Env incorporation into virions. Journal of virology. 2000; 74(10):4891–3.
Epub 2000/04/25. PMID: 10775630; PubMed Central PMCID: PMC112014.
89. Iwatani Y, Ueno T, Nishimura A, Zhang X, Hattori T, Ishimoto A, et al. Modification of virus infectivity
by cytoplasmic tail of HIV-1 TM protein. Virus Res. 2001; 74(1–2):75–87. Epub 2001/02/28. PMID:
11226576.
90. Jiang J, Aiken C. Maturation-dependent human immunodeficiency virus type 1 particle fusion requires
a carboxyl-terminal region of the gp41 cytoplasmic tail. Journal of virology. 2007; 81(18):9999–10008.
Epub 2007/07/05. JVI.00592-07 [pii] doi: 10.1128/JVI.00592-07 PMID: 17609279; PubMed Central
PMCID: PMC2045384.
91. Beaumont E, Vendrame D, Verrier B, Roch E, Biron F, Barin F, et al. Matrix and envelope coevolution
revealed in a patient monitored since primary infection with human immunodeficiency virus type 1.
Journal of virology. 2009; 83(19):9875–89. Epub 2009/07/25. doi: 10.1128/JVI.01213-09 PMID:
19625403; PubMed Central PMCID: PMC2748007.
92. Salemi M, de Oliveira T, Soares MA, Pybus O, Dumans AT, Vandamme AM, et al. Different epidemic
potentials of the HIV-1B and C subtypes. Journal of molecular evolution. 2005; 60(5):598–605. PMID:
15983869.
93. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quinones-Mateu ME, et al. Comparing the ex
vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. Jour-
nal of virology. 2003; 77(2):1021–38. PMID: 12502818.
94. Rangel HR, Weber J, Chakraborty B, Gutierrez A, Marotta ML, Mirza M, et al. Role of the human
immunodeficiency virus type 1 envelope gene in viral fitness. Journal of virology. 2003; 77(16):9069–
73. Epub 2003/07/30. PMID: 12885922; PubMed Central PMCID: PMC167250.
95. Pollakis G, Abebe A, Kliphuis A, Chalaby MI, Bakker M, Mengistu Y, et al. Phenotypic and genotypic
comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones iso-
lated from subtype C-infected individuals. Journal of virology. 2004; 78(6):2841–52. PMID: 14990703.
96. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, VanhamG, Arts EJ. The replicative fitness of
primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.
Journal of virology. 2005; 79(14):8979–90. PMID: 15994792.
97. Arts EJ. Infection with subtype C HIV-1 of lower replicative fitness as compared to subtypes A and D
leads to slower disease progression in Zimbabwean and Ugandan women. 2006.
98. Perez-Bercoff D, Wurtzer S, Compain S, Benech H, Clavel F. Human immunodeficiency virus type 1:
resistance to nucleoside analogues and replicative capacity in primary humanmacrophages. Journal
of virology. 2007; 81(9):4540–50. Epub 2007/02/09. JVI.01620-06 [pii] doi: 10.1128/JVI.01620-06
PMID: 17287264; PubMed Central PMCID: PMC1900139.
99. Struck D, Lawyer G, Ternes AM, Schmit JC, Perez Bercoff D. COMET: adaptive context-based
modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014. doi: 10.1093/nar/gku739
PMID: 25120265.
100. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated
genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005; 21
(19):3797–800. Epub 2005/08/04. bti607 [pii] doi: 10.1093/bioinformatics/bti607 PMID: 16076886.
101. Mulinge M, Lemaire M, Servais JY, Rybicki A, Struck D, da Silva ES, et al. HIV-1 Tropism Determina-
tion Using a Phenotypic Env Recombinant Viral Assay Highlights Overestimation of CXCR4-Usage
by Genotypic Prediction Algorithms for CRRF01_AE and CRF02_AG. PLoS One. 2013; 8(5):e60566.
Epub 2013/05/15. doi: 10.1371/journal.pone.0060566 PMID: 23667426; PubMed Central PMCID:
PMC3648519.
102. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, et al. Production of acquired immu-
nodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infec-
tious molecular clone. Journal of virology. 1986; 59(2):284–91. PMID: 3016298.
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 26 / 29
103. Freed EO, Englund G, Martin MA. Role of the basic domain of human immunodeficiency virus type 1
matrix in macrophage infection. Journal of virology. 1995; 69(6):3949–54. Epub 1995/06/01. PMID:
7745752; PubMed Central PMCID: PMC189124.
104. Van Laethem K, Schrooten Y, Lemey P, VanWijngaerden E, DeWit S, Van Ranst M, et al. A geno-
typic resistance assay for the detection of drug resistance in the human immunodeficiency virus type
1 envelope gene. J Virol Methods. 2005; 123(1):25–34. doi: 10.1016/j.jviromet.2004.09.003 PMID:
15582695.
105. Baatz F, Nijhuis M, Lemaire M, Riedijk M, Wensing AM, Servais JY, et al. Impact of the HIV-1 env
genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in
clinical isolates. PLoS One. 2011; 6(7):e21535. Epub 2011/07/16. doi: 10.1371/journal.pone.0021535
PONE-D-11-05167 [pii]. PMID: 21760896; PubMed Central PMCID: PMC3132734.
106. Jacobs GB, Bock S, Schuch A, Moschall R, Schrom EM, Zahn J, et al. Construction of a high titer
infectious HIV-1 subtype C proviral clone from South Africa. Viruses. 2012; 4(9):1830–43. Epub 2012/
11/22. doi: 10.3390/v4091830 PMID: 23170185; PubMed Central PMCID: PMC3499832.
107. Gousset K, Ablan SD, Coren LV, Ono A, Soheilian F, Nagashima K, et al. Real-time visualization of
HIV-1 GAG trafficking in infected macrophages. PLoS Pathog. 2008; 4(3):e1000015. Epub 2008/03/
29. doi: 10.1371/journal.ppat.1000015 PMID: 18369466; PubMed Central PMCID: PMC2267008.
108. Sharova N, Swingler C, Sharkey M, Stevenson M. Macrophages archive HIV-1 virions for dissemina-
tion in trans. EMBO J. 2005; 24(13):2481–9. Epub 2005/05/28. 7600707 [pii] doi: 10.1038/sj.emboj.
7600707 PMID: 15920469; PubMed Central PMCID: PMC1173148.
109. Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, Marsh M. In macrophages, HIV-1 assem-
bles into an intracellular plasmamembrane domain containing the tetraspanins CD81, CD9, and
CD53. J Cell Biol. 2007; 177(2):329–41. PMID: 17438075.
110. Welsch S, Keppler OT, Habermann A, Allespach I, Krijnse-Locker J, Krausslich HG. HIV-1 buds pre-
dominantly at the plasmamembrane of primary humanmacrophages. PLoS Pathog. 2007; 3(3):e36.
PMID: 17381240.
111. Jouve M, Sol-Foulon N, Watson S, Schwartz O, Benaroch P. HIV-1 buds and accumulates in "non-
acidic" endosomes of macrophages. Cell Host Microbe. 2007; 2(2):85–95. Epub 2007/11/17. S1931-
3128(07)00159-X [pii] doi: 10.1016/j.chom.2007.06.011 PMID: 18005723.
112. Koppensteiner H, Banning C, Schneider C, Hohenberg H, Schindler M. Macrophage internal HIV-1 is
protected from neutralizing antibodies. Journal of virology. 2012; 86(5):2826–36. Epub 2011/12/30.
doi: 10.1128/JVI.05915-11 PMID: 22205742; PubMed Central PMCID: PMC3302290.
113. Constantino AA, Huang Y, Zhang H, Wood C, Zheng JC. HIV-1 clade B and C isolates exhibit differen-
tial replication: relevance to macrophage-mediated neurotoxicity. Neurotox Res. 2011; 20(3):277–88.
doi: 10.1007/s12640-011-9241-3 PMID: 21336667; PubMed Central PMCID: PMCPMC3407549.
114. Carr JM, Hocking H, Li P, Burrell CJ. Rapid and efficient cell-to-cell transmission of human immunode-
ficiency virus infection frommonocyte-derived macrophages to peripheral blood lymphocytes. Virol-
ogy. 1999; 265(2):319–29. Epub 1999/12/22. doi: 10.1006/viro.1999.0047 S0042-6822(99)90047-8
[pii]. PMID: 10600603.
115. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, Martin MA. Quantitation of human immuno-
deficiency virus type 1 infection kinetics. Journal of virology. 1993; 67(4):2182–90. Epub 1993/04/01.
PMID: 8445728; PubMed Central PMCID: PMC240333.
116. Johnson DC, Huber MT. Directed egress of animal viruses promotes cell-to-cell spread. Journal of
virology. 2002; 76(1):1–8. Epub 2001/12/12. PMID: 11739666; PubMed Central PMCID:
PMC135733.
117. Rudnicka D, Feldmann J, Porrot F, Wietgrefe S, Guadagnini S, Prevost MC, et al. Simultaneous cell-
to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. Jour-
nal of virology. 2009; 83(12):6234–46. Epub 2009/04/17. JVI.00282-09 [pii] doi: 10.1128/JVI.00282-
09 PMID: 19369333; PubMed Central PMCID: PMC2687379.
118. Dale BM, Alvarez RA, Chen BK. Mechanisms of enhanced HIV spread through T-cell virological syn-
apses. Immunological reviews. 2013; 251(1):113–24. doi: 10.1111/imr.12022 PMID: 23278744.
119. Murooka TT, Deruaz M, Marangoni F, Vrbanac VD, Seung E, von Andrian UH, et al. HIV-infected T
cells are migratory vehicles for viral dissemination. Nature. 2012; 490(7419):283–7. doi: 10.1038/
nature11398 PMID: 22854780; PubMed Central PMCID: PMC3470742.
120. Durham ND, Chen BK. HIV-1 Cell-Free and Cell-to-Cell Infections Are Differentially Regulated by Dis-
tinct Determinants in the Env gp41 Cytoplasmic Tail. Journal of virology. 2015; 89(18):9324–37. doi:
10.1128/JVI.00655-15 PMID: 26136566; PubMed Central PMCID: PMCPMC4542346.
121. Emerson V, Holtkotte D, Pfeiffer T, Wang IH, Schnolzer M, Kempf T, et al. Identification of the cellular
prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 27 / 29
the HIV-1 glycoprotein. Journal of virology. 2010; 84(3):1355–65. Epub 2009/11/13. JVI.01641-09 [pii]
doi: 10.1128/JVI.01641-09 PMID: 19906925; PubMed Central PMCID: PMC2812343.
122. De Candia C, Espada C, Duette G, Ghiglione Y, Turk G, Salomon H, et al. Viral replication is
enhanced by an HIV-1 intersubtype recombination-derived Vpu protein. Virol J. 2010; 7:259. doi: 10.
1186/1743-422X-7-259 PMID: 20920359; PubMed Central PMCID: PMC2967538.
123. Ruiz A, Schmitt K, Culley N, Stephens EB. Simian-Human immunodeficiency viruses expressing chi-
meric subtype B/C Vpu proteins demonstrate the importance of the amino terminal and transmem-
brane domains in the rate of CD4(+) T cell loss in macaques. Virology. 2013; 435(2):395–405. doi: 10.
1016/j.virol.2012.10.030 PMID: 23218949.
124. Gottlinger HG, Dorfman T, Sodroski JG, HaseltineWA. Effect of mutations affecting the p6 gag protein
on human immunodeficiency virus particle release. Proceedings of the National Academy of Sciences
of the United States of America. 1991; 88(8):3195–9. PMID: 2014240; PubMed Central PMCID:
PMC51412.
125. Fultz PN, Vance PJ, Endres MJ, Tao B, Dvorin JD, Davis IC, et al. In vivo attenuation of simian immu-
nodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein
cytoplasmic tail. Journal of virology. 2001; 75(1):278–91. doi: 10.1128/JVI.75.1.278–291.2001 PMID:
11119598; PubMed Central PMCID: PMCPMC113922.
126. Pan Z, Radding W, Zhou T, Hunter E, Mountz J, McDonald JM. Role of calmodulin in HIV-potentiated
Fas-mediated apoptosis. Am J Pathol. 1996; 149(3):903–10. Epub 1996/09/01. PMID: 8780394;
PubMed Central PMCID: PMC1865159.
127. RaddingW, Pan ZQ, Hunter E, Johnston P, Williams JP, McDonald JM. Expression of HIV-1 envelope
glycoprotein alters cellular calmodulin. Biochem Biophys Res Commun. 1996; 218(1):192–7. Epub
1996/01/05. PMID: 8573130.
128. Micoli KJ, Pan G, Wu Y, Williams JP, CookWJ, McDonald JM. Requirement of calmodulin binding by
HIV-1 gp160 for enhanced FAS-mediated apoptosis. The Journal of biological chemistry. 2000; 275
(2):1233–40. Epub 2000/01/08. PMID: 10625668.
129. Centlivre M, Sommer P, Michel M, Ho Tsong Fang R, Gofflo S, Valladeau J, et al. The HIV-1 clade C
promoter is particularly well adapted to replication in the gut in primary infection. AIDS (London,
England). 2006; 20(5):657–66. doi: 10.1097/01.aids.0000216365.38572.2f PMID: 16514295.
130. Sala M, Centlivre M, Wain-Hobson S. Clade-specific differences in active viral replication and
compartmentalization. Curr Opin HIV AIDS. 2006; 1(2):108–14. doi: 10.1097/01.COH.0000203835.
01350.b4 PMID: 19372793.
131. Centlivre M, Sommer P, Michel M, Ho Tsong Fang R, Gofflo S, Valladeau J, et al. HIV-1 clade promot-
ers strongly influence spatial and temporal dynamics of viral replication in vivo. J Clin Invest. 2005;
115(2):348–58. doi: 10.1172/JCI22873 PMID: 15690084; PubMed Central PMCID: PMC546425.
132. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodefi-
ciency virus in T cells. Nature. 1987; 326(6114):711–3. Epub 1987/04/16. doi: 10.1038/326711a0
PMID: 3031512.
133. Van Laethem K, Schrooten Y, Dedecker S, Van Heeswijck L, Deforche K, VanWijngaerden E, et al. A
genotypic assay for the amplification and sequencing of gag and protease from diverse human immu-
nodeficiency virus type 1 group M subtypes. J Virol Methods. 2006; 132(1–2):181–6. Epub 2005/11/
08. doi: 10.1016/j.jviromet.2005.10.008 PMID: 16271771.
134. Durham ND, Yewdall AW, Chen P, Lee R, Zony C, Robinson JE, et al. Neutralization resistance of
virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail. Journal of
virology. 2012; 86(14):7484–95. Epub 2012/05/04. doi: 10.1128/JVI.00230-12 PMID: 22553332;
PubMed Central PMCID: PMC3416307.
135. Brandano L, Stevenson M. A highly conserved residue in the C-terminal helix of HIV-1 matrix is
required for envelope incorporation into virus particles. Journal of virology. 2012; 86(4):2347–59. doi:
10.1128/JVI.06047-11 PMID: 22156517; PubMed Central PMCID: PMC3302379.
136. Tedbury PR, Ablan SD, Freed EO. Global Rescue of Defects in HIV-1 Envelope Glycoprotein Incorpo-
ration: Implications for Matrix Structure. PLoS Pathog. 2013; 9(11):e1003739. doi: 10.1371/journal.
ppat.1003739 PMID: 24244165; PubMed Central PMCID: PMC3828165.
137. Facke M, Janetzko A, Shoeman RL, Krausslich HG. A large deletion in the matrix domain of the
human immunodeficiency virus gag gene redirects virus particle assembly from the plasmamem-
brane to the endoplasmic reticulum. Journal of virology. 1993; 67(8):4972–80. PMID: 8331736;
PubMed Central PMCID: PMC237885.
138. Yu X, Yuan X, McLaneMF, Lee TH, Essex M. Mutations in the cytoplasmic domain of human immuno-
deficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature
virions. Journal of virology. 1993; 67(1):213–21. PMID: 8416370.
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 28 / 29
139. Batonick M, Favre M, Boge M, Spearman P, Honing S, Thali M. Interaction of HIV-1 Gag with the cla-
thrin-associated adaptor AP-2. Virology. 2005; 342(2):190–200. Epub 2005/09/06. doi: 10.1016/j.
virol.2005.08.001 PMID: 16139856.
140. Liu L, Sutton J, Woodruff E, Villalta F, Spearman P, Dong X. Defective HIV-1 particle assembly in AP-
3-deficient cells derived from patients with Hermansky-Pudlak syndrome type 2. Journal of virology.
2012; 86(20):11242–53. doi: 10.1128/JVI.00544-12 PMID: 22875976; PubMed Central PMCID:
PMC3457180.
141. Yuan X, Yu X, Lee TH, Essex M. Mutations in the N-terminal region of human immunodeficiency virus
type 1 matrix protein block intracellular transport of the Gag precursor. Journal of virology. 1993; 67
(11):6387–94. PMID: 8411340; PubMed Central PMCID: PMC238073.
142. Ono A, Orenstein JM, Freed EO. Role of the Gag matrix domain in targeting human immunodeficiency
virus type 1 assembly. Journal of virology. 2000; 74(6):2855–66. Epub 2000/02/23. PMID: 10684302;
PubMed Central PMCID: PMC111776.
143. Spearman P, Wang JJ, Vander Heyden N, Ratner L. Identification of human immunodeficiency virus
type 1 Gag protein domains essential to membrane binding and particle assembly. Journal of virology.
1994; 68(5):3232–42. PMID: 8151785; PubMed Central PMCID: PMC236814.
144. Freed EO, Orenstein JM, Buckler-White AJ, Martin MA. Single amino acid changes in the human
immunodeficiency virus type 1 matrix protein block virus particle production. Journal of virology. 1994;
68(8):5311–20. PMID: 8035531; PubMed Central PMCID: PMC236481.
145. Tang C, Loeliger E, Luncsford P, Kinde I, Beckett D, Summers MF. Entropic switch regulates myris-
tate exposure in the HIV-1 matrix protein. Proceedings of the National Academy of Sciences of the
United States of America. 2004; 101(2):517–22. Epub 2003/12/31. doi: 10.1073/pnas.0305665101
PMID: 14699046; PubMed Central PMCID: PMC327179.
146. Fledderman EL, Fujii K, Ghanam RH, Waki K, Prevelige PE, Freed EO, et al. Myristate exposure in
the human immunodeficiency virus type 1 matrix protein is modulated by pH. Biochemistry. 2010; 49
(44):9551–62. doi: 10.1021/bi101245j PMID: 20886905; PubMed Central PMCID: PMC3032006.
Polymorphisms in the HIV gp41CT Decrease Viral Infectivity and Cell-to-Cell Trasmission
PLOS ONE | DOI:10.1371/journal.pone.0161596 September 6, 2016 29 / 29
